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 Abstract 
Type 2 Diabetes (T2D) is a debilitating complex disease that affects approximately 8% of 
the worldwide population. Diabetic retinopathy, the major microvascular complication of this 
disease is one of the leading causes of adult blindness in T2D patients. K
genetic basis underlying this vascular diabetic complication will help understand the 
pathobiology and ameliorate the standard means of diagnosis, treatment and patient 
management. We proposed and pursued with this project and with the use 
analysis and next-generation sequencing techniques to identify candidate genetic markers that 
predispose to the onset of Diabetic Retinopathy. Our study population was a group of 40 
patients selected from the Type 2 Diabetes population of di
associated complications, from the Endocrinology Unit of the Hospital Center of the University 
of Coimbra. The workflow was, exome library preparation and parallel sequencing by Ion 
Torrent technology. The search for candi
variants was performed by differentiated bioinformatics and statistical approaches. Eleven 
candidate common variants (rs1035798, rs62357156, rs7125062, rs80067372, rs4434138, 
rs4234633, rs10794640, rs9907595,
MMP1, TNFSF12, STAB1, NARFL, PLXDC1, PRKCQ, GSTM3 and EGF and 2 rare variant 
accumulating genes, E2F8 and DMXL2 were considered biologically relevant. These variants 
were localized in genes involved i
pathogenesis such as Advanced Glycated End (AGE) products trafficking and 
fibrovascular membrane formation, EGF
angiogenesis, vascular assembly and morphogenesis and the Notch signalling pathway. 
Validation of the technology, variants and allele frequencies was performed by other 
sequencing and genotyping methods. This study highlighted several new candidate biomarkers 
that need to be validated in a larger population before association to Diabetic Retinopathy.
 
Keywords: Diabetic Retinopathy, Exome Sequencing, Genetic Markers, Rare Variants, 
Common Variants  
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 Resumo 
A Diabetes Tipo 2 (DT2) é uma doença complexa e debilitadora que 
aproximadamente 8% da população mundial. A Retinopatia Diabética, a maior complicação 
microvascular desta doença, é uma das principais causas de cegueira em adultos 
diagnosticados com Diabetes Tipo 2. O conhecimento da base genética subjacente a esta 
complicação vascular permitirá uma melhor compreensão da doença e consequente aplicação 
de meios efetivos de diagnóstico, tratamento e gestão d
com a utilização de sequenciação de exomas com técnicas de última geração, id
marcadores genéticos candidatos que predispõem para o desenvolvimento da Retinopatia 
Diabética. A nossa população 
de doentes Portugueses diagnosticados com Diabetes do Tipo 2, com di
associadas, da Unidade de Endocrinologia do Centro Hospitalar da Universidade de Coimbra. A 
metodologia utilizada foi extração de 
sequenciação massiva paralela pela tecnologia Ion 
acumulam variantes raras e de variantes comuns foi realizada por diferentes abordagens 
bioinformáticas e estatísticas. Dois genes que acumulam variantes raras, E2F8 e DMXL2, e onze 
variantes comuns (rs1035798, rs62357156, r
rs10794640, rs9907595, rs2296123, rs7483 e rs4698803) nos genes: AGER, ITGA1, MMP1, 
TNFSF12, STAB1, NARFL, PLXDC1, PRKCQ, GSTM3 e EGF foram considerados biologicamente 
relevantes. As variantes encontradas localiz
relacionadas com a patogénese da Retinopatia Diabética, tais como a via de sinalização e 
tráfego de produtos finais de glicação avançados, formação de membrana fibrovascular, via de 
sinalização EGF-VEGF, angio
vascular e a via de sinalização Notch. A validação da tecnologia, variantes e frequências alélicas 
foi realizada por diferentes métodos de sequenciação e genotipagem. Este estudo destacou 
alguns biomarcadores candidatos, que carecem de validação numa população maior antes de 
poderem ser associados à retinopatia diabética.
 
Palavras Chave: Retinopatia Diabética, Sequenciação de Exomas, Marcadores Genéticos, 
Variantes Raras, Variantes Comuns
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Chapter 1 
Introduction and Literature review 
 
  
 2 
 
1. Introduction and Literature review 
1.1 Introduction 
 
Understanding the genetics of common, complex and debilitating disorders 
continues to be a challenge
 
and although the recognition of its importance, genetic 
analysis are difficult due to the complex interaction among multiple susceptibility 
genes and between genetic and environmental factors
 
(Doria, 2010; van Hoek et al., 
2008; Herder & Roden, 2011; Lyssenko & Laakso, 2013; Lyssenko et al., 2005 and 
Frazer et al., 2009).  
Research of the genetic causes of Type 2 Diabetes and its microvascular 
complication, Diabetic Retinopathy (DR), has been and remains a demanding area of 
interest (Lohmueller et al., 2013). Some genes have been implicated in the aetiology of 
the disorder but replication of these findings has been difficult and genetic studies 
have revealed diverse results (Weedon et al., 2006; Lohmueller et al., 2013; Kuo et al., 
2014).  
Over the past years, new techniques, such as whole genome analysis through Next-
generation sequencing and the availability of large population-based DNA banks have 
accelerated research and knowledge of the genetics of common diseases. Whole 
Exome Sequencing being a comprehensive, cost efficient and rapid method for 
analysing and studying the coding regions of an individual is a useful tool in complex 
traits genetics (Bonnefond et al., 2010; Johansson et al., 2012; Bamshad et al., 2011; 
Albrechtsen et al., 2013). It allows for an extensive genetic search and may unravel 
completely novel genes or variants in individuals with no genetic defect in the known 
diabetic retinopathy genes (Johansson et al., 2012). 
The ultimate goal of this line of research, as with nearly all research in the genetics 
of any complex disease, is to improve the understanding of the pathophysiology and 
disease aetiology so that more effective means of diagnosis, treatment and prevention 
can be developed (Manolio, 2009; Bamshad et al., 2011).  
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1.2. Literature Review 
1.2.1 Fundamentals of Type 2 Diabetes 
Type 2 Diabetes (T2D) is a slow and progressive endocrine disorder (Kahn, 1994) 
characterized by impaired insulin secretion and variable degrees of insulin resistance 
(Figure 1) that leads to an elevation in blood glucose, hyperglycaemia, which in time 
results in debilitating complications and damage to various organs (Anomalies & Brief, 
2003; Olokoba et al., 2012). 
 
 
Figure 1. Differences between the normal glucose absorption process in a healthy individual (A) and the 
insulin resistance condition in a T2D diagnosed individual (B).  
In the exemplified case (B), the stomach converts food to glucose which enters the bloodstream. The 
pancreas produces sufficient insulin but it is resistant to effective use. Thus glucose absorption is inefficient 
and glucose blood levels are increased. Adapted from http://www.topnews.in/health/scientists-illuminate-
cell-pathway-key-insulin-resistance-type-2-diabetes-211013. 
 
T2D is the most common form of diabetes worldwide accounting for 90-95% of all 
cases (Massi-Benedetti, 2002; American Diabetes Association, 2014; Olokoba et al., 
2012). The progression from having a genetic predisposition to T2D and the 
development of an elevated blood sugar and hence the disease is affected by 
environmental factors such as being overweight, physical inactivity, age, diet, illness, 
pregnancy, medication and on how strong the gene traits are causing the disorder in 
that individual (Kahn, 1994; Reis & Velho, 2002; Olokoba et al., 2012). 
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1.2.1.1 Epidemiology 
This disease has reached epidemic proportions worldwide and although has always 
been associated to older ages, its prevalence has been increasing in children and 
adolescents due to the widespread of obesity, particularly central obesity, and 
unhealthy lifestyles. (Anomalies & Brief, 2003; Bloomgarden,
 
2004). 
Globally in 2013, it was estimated that almost 382 million adults (20-79 years) 
suffered from T2D for a prevalence of 8.3%, whereas in Europe, almost 52 million 
adults suffered from this complex disease, with a prevalence of 7.9% (Martinez, 2013) 
(Figure 2). Of these, 33% (17.2 million) had not been diagnosed and were at a higher 
risk of developing harmful and costly complications. Half of the individuals that 
clinically present T2D already present signs of the associated complications (Mathers & 
Loncar, 2006) and the identification of these individuals is of great importance and 
interest for health care providers and investigators (Lyssenko & Laakso, 2013).  
 
 
Figure 2. Worldwide Prevalence of Diabetes Type 2. 
The percentage of undiagnosed individuals is highest among poorer countries such as Middle East and 
North Africa, South East Asia, Western Pacific and Africa. Adapted from IDF Diabetes Atlas, Sixth Edition, 
2014 Update (Martinez, 2013). 
 
Unless action is taken it is predicted that, by the year 2035, there will be 
approximately 69 million T2D adults in Europe, with a prevalence of 10.3%.
 
(Martinez, 
2013). It is a major health problem all over the world with its greatest impact being in 
newly industrialized and developing nations and minority groups in developed 
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countries (Massi-Benedetti 2002; Olokoba et al., 2012). The socio-economic and public 
health impact of the disease is constantly increasing and has effects on the work force, 
time taken for treatment, premature morbidity and mortality (Massi-Benedetti, 2002). 
In 2014, Diabetes caused 537,000 deaths in Europe and 23% of these deaths were in 
people under the age of 60 (Martinez, 2013). 
In 2013 the estimated prevalence of Diabetes in the Portuguese population with 
ages between 20 and 79 years, corresponding to 7.8 million individuals, was 13,0%, 
this is, more than 1 million Portuguese people, in this age group, had Diabetes (OND, 
2014). The comparative prevalence in Europe was 9.57% (Figure 3). 
 
 
Figure 3. European Prevalence of Diabetes Type 2 in adults (20-79 years). 
The number of cases in thousands, comparative prevalence (%), related deaths and mortality (x100 
000population) in Portugal is highlighted. Adapted from Prevalence of Diabetes in the World, 2013 
(Martinez, 2013). http://healthintelligence.drupalgardens.com/content/prevalence-diabetes-world-2013 
 
Considering only the Portuguese population diagnosed with Diabetes between 
20 and 79 years, in 2013, the national health expenses were 962 million Euros, for all 
individuals. This represented 1% of the Gross National Product and 10% of all health 
expenses. It is estimated that the national prevalence of Diabetes, in 2035, in Portugal, 
will be 15.8%. (Figure 4) which will naturally increase the health costs associated. 
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Figure 4. Estimates for the prevalence of Diabetes Type 2 in adults (20-79 years), in Europe for 2035. 
The comparative prevalence has been calculated by assuming that every country and region has the same 
age profile (world population) reducing the effect of age differences between countries and regions. 
Adapted from IDF Diabetes Atlas, Sixth Edition, 2014 Update (Martinez, 2013). 
http://www.idf.org/atlasmap/atlasmap?indicator=i1&date=2014)  
 
T2D is strongly inherited and proof of the genetic factor cause is evidenced by 
the high prevalence of the disease in certain racial and ethnic groups such as Hispanics, 
Asians, Pacific Islanders, African and Native Americans, Southeast Asians and the 
higher risk inherent to belonging to a family with a history of T2D (Anomalies & Brief, 
2003; American Diabetes Association, 2014; Reis & Velho, 2002;Barroso et al., 2003). 
 
1.2.1.2 Pathophysiology of Type 2 Diabetes 
Pathogenesis of this complex disease is still incompletely understood. Although 
insulin resistance is characteristic in T2D individuals, evidence also exists for β-cell 
dysfunction. High glucose levels may desensitize β-cells (glucose toxicity) and impair 
insulin secretion. It is however unlikely that glucotoxicity acts alone, and the negative 
contribution of saturated fatty acids, lipoproteins, leptin and circulating and locally 
produced cytokines will further burn out the β-cells (Kahn, 1994). 
A long time has passed since the idea that insulin solely binds to its receptor 
leading to the stimulation of glucose transport. In the past decades cellular and 
molecular biology techniques have greatly enhanced the understanding of the insulin 
process. Many proteins involved in the insulin action cascade have been identified and 
cloned at the molecular level giving a new insight into the fascinating and complex 
process of insulin action in the cell (Figure 5).  
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Figure 5. Insulin Receptor Signalling Cascade. 
Insulin is the major hormone controlling critical energy functions such as glucose and lipid metabolism. 
Insulin activates the insulin receptor tyrosine kinase (IR), which phosphorylates and recruits different 
substrate adaptors such as the IRS family of proteins. Tyrosine phosphorylated IRS then displays binding 
sites for numerous signaling partners. Among them, PI3K has a major role in insulin function, mainly via the 
activation of the Akt/PKB and the PKCζ cascades. Activated Akt induces glycogen synthesis through 
inhibition of GSK-3; protein synthesis via mTOR and downstream elements; and cell survival through 
inhibition of several pro-apoptotic agents (Bad, FoxO transcription factors, GSK-3, and MST1). Insulin 
signaling also has growth and mitogenic effects, which are mostly mediated by the Akt cascade as well as by 
activation of the Ras/MAPK pathway. The insulin signaling pathway inhibits autophagy via the ULK1 kinase, 
which is inhibited by Akt and mTORC1, and activated by AMPK. Insulin stimulates glucose uptake in muscle 
and adipocytes via translocation of GLUT4 vesicles to the plasma membrane. GLUT4 translocation involves 
the PI3K/Akt pathway and IR-mediated phosphorylation of CAP, and formation of the CAP:CBL:CRKII 
complex. In addition, insulin signaling inhibits gluconeogenesis in the liver, through disruption of 
CREB/CBP/mTORC2 binding. Insulin signaling induces fatty acid and cholesterol synthesis via the regulation 
of SREBP transcription factors. Insulin signaling also promotes fatty acid synthesis through activation of 
USF1 and LXR. A negative feedback signal emanating from Akt/PKB, PKCζ, p70 S6K, and the MAPK cascades 
results in serine phosphorylation and inactivation of IRS signaling.Adapted from Cell Signaling Technology 
(http://www.cellsignal.com/contents/science-cst-pathways-cellular-metabolism/insulin-receptor-
signaling-pathway/pathways-irs?Ntt=insulin+receptor&fromPage=search) 
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For simplicity, we may think of insulin action occurring at three levels or stages 
(Kahn, 1994) (Figure 6).
 
Level 1 is composed of the initial events related to receptor 
tyrosine kinase activity. This includes the insulin receptor itself, the insulin receptor 
substrate, and the molecules that interact with this substrate. Level 2 refers to the 
cascade of serine phosphorylation and dephosphorylation reactions centered on the 
enzyme MAP (mitogen-activated protein/microtubule-associated protein) kinase. Level 
3 is the final biological effectors of the insulin cascade. This includes the glucose 
transport molecules themselves, which reside in an intracellular pool and are 
translocated to the plasma membrane following insulin stimulation, the enzymes for 
glycogen and lipid synthesis and the proteins involved in insulin action on gene 
expression and cell growth (Kahn, 1994). 
 
 
Figure 6. The Three levels of insulin action: molecules and pathways involved in insulin signaling (Kahn, 
1994).  
 
1.2.1.3 Associated Complications  
It is predicted that by 2030, Diabetes will be the 7th leading cause of worldwide 
death (Mathers & Loncar, 2006), primarily due to complications associated with end 
organ damage including heart disease, stroke, blindness, kidney disease, peripheral 
neuropathy and amputations (Anomalies & Brief, 2003; Massi-Benedetti, 2002; 
American Diabetes Association, 2014). 
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Poorly controlled hyperglycemia leads to multiple vascular complications that affect 
small (microvascular) and/or large (macrovascular) vessels (Massi-Benedetti 2002). 
These vascular complications involve several important organs such as eyes, kidneys 
and the cardiovascular system (Tang et al., 2013) (Figure 7). The mechanisms by which 
vascular disease develops include: 1) glycosylation of serum and tissue proteins with 
formation of advanced glycation end products; 2) superoxide production; 3) activation 
of protein kinase C, a signaling molecule that increases vascular permeability and 
causes endothelial dysfunction; 4) accelerated hexosamine biosynthetic and polyol 
pathways leading to sorbitol accumulation within tissues; 5) hypertension and 
dyslipidemias (abnormal accumulation of lipids in the blood); 6) arterial 
microthromboses; pro-inflammatory and pro-thrombotic effects and 7) 
hyperinsulinemia that impairs vascular autoregulation (Massi-Benedetti 2002). 
Immune dysfunction is another major complication and develops from the direct 
effects of hyperglycemia on cellular immunity (Kishore, 2013). 
The microvascular diseases that may appear are Diabetic Retinopathy, the most 
common cause of adult blindness characterized initially by retinal capillary 
microaneurysms and later by macular edema and neovascularisation; Diabetic 
Nephropathy, a leading cause of chronic renal failure characterized by the thickening 
of the glomerular basement membrane, mesangial expansion and glomerular sclerosis 
and Diabetic Neuropathy, resulting from nerve ischemia by the direct effects of 
hyperglycemia on neurons and intracellular metabolic changes that impair nerve 
function (Massi-Benedetti 2002). 
Large vessel atherosclerosis, a macrovascular disease, manifests by myocardial 
infarctions, transient ischemic attacks, strokes and peripheral arterial disease (Massi-
Benedetti 2002; Kishore, 2013). 
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Figure 7. Diabetes complications. 
Conditions or pathological processes associated with the disease of diabetes mellitus due to the impaired 
control of blood glucose level in diabetic patients, pathological processes develop in numerous tissues and 
organs including the eye, the kidney, the blood vessels and the nerve tissue.  
Adapted from http://lookfordiagnosis.com/mesh_info.php?term=Diabetes+Complications&lang=1 
 
Diabetic foot complications such as skin change, ulceration, infection and 
gangrene are common in T2D individuals and attributable to vascular disease, 
neuropathy and immunosuppression (Massi-Benedetti 2002; Kishore, 2013). 
As for the psychosocial impacts of T2D, depression is a common problem and 
may precede the development of the disease. Diabetic individuals with untreated 
depression have poorer glucose control, increased risk of complications and higher 
health care costs (Anomalies & Brief, 2003).
 
Adequate prevention and management of 
T2D may require significant behavioural change which can reveal frustrating for 
patients and health care providers. Yet, the psychosocial and behavioural impacts of 
knowing the genetic risk for T2D has not been assessed (Anomalies & Brief, 2003).
 
1.2.2 Fundamentals of Diabetic Retinopathy  
Published evidence indicates that major risk factors, such as long term diabetes, 
poor control of blood glucose and elevated blood pressure are responsible for the 
onset and progression of diabetic complications (Tang et al., 2013; Kuo et al., 2014). 
Nonetheless these clinical features have not been consistently identified in different 
studies and patients cannot be stratified with respect to their risk of developing a 
microvascular complication based only upon clinical or procedural risk factors. There is 
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now evidence that genetic factors may explain part of the excessive risk independently 
of conventional clinical variables (Tang et al., 2013). 
Diabetic Retinopathy is a common complications of diabetes, in which the retina 
becomes progressively damaged, leading to vision loss and blindness (Nawaz, 2010) 
and the duration of diabetes is probably the strongest predictor for development and 
progression of retinopathy (Fong et al., 2004, Kuo et al., 2014). 
1.2.2.1 Anatomy-physiology of the Human Eye 
The retina is a thin layer of light-sensitive tissue that lines the back of the eye. 
Light rays are focused onto the retina, where they are transmitted to the brain and 
interpreted as images. The macula is a small area at the centre of the retina that is 
responsible for pinpoint vision. The surrounding part of the retina, called the 
peripheral retina, is responsible for peripheral vision (Figure 8). 
 
 
Figure 8. Normal vs Diabetic Retinopathy Eye. 
Diabetic Retinopathy affects the blood vessels in the retina, leading to new abnormal blood vessel growth, 
leakage and bleeding. Adapted from http://www.diabetest1ireland.com/eye-damage.html 
 
Diabetic retinopathy thus occurs when blood vessels in the retina swell and leak 
fluid or even close off completely. In aggravated cases abnormal new blood vessels 
grow on the surface of the retina. As the disease progresses various symptoms appear: 
spots, dots or dark strings floating, floaters (Figure 9); blurred vision; blank or dark 
areas in the vision field; poor night vision; colours appear washed and vision loss. 
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Figure 9. Diabetic Retinopathy Symptoms. 
Presence of floaters in the vision field. Adapted from http://eyedoctorwichita.com/eye---vision-
problems/diabetic-retinopathy.html 
 
1.2.2.2 Clinical Classification of Diabetic Retinopathy 
Diabetic Retinopathy progresses from mild non-proliferative abnormalities, 
characterized by increased vascular permeability, to moderate and severe non-
proliferative diabetic retinopathy (NPDR), characterized by vascular closure. 
Proliferative diabetic retinopathy (PDR) is characterized by the growth of new blood 
vessels on the retina and posterior surface of the vitreous. Macular edema, the retinal 
thickening from leaky blood vessels, can develop at all stages of retinopathy (Fong et 
al., 2004) (Figure 10). Although proliferative retinopathy may lead to loss of vision and 
blindness, diabetic macular edema (DME) is the main cause of central vision loss. 
(Ozturk et al., 2009) 
 
 
Figure 10. Non-proliferative vs Proliferative Diabetic Retinopathy. 
In non-proliferative DR aneurysms, hard exudates and hemorrhages may occur whereas in proliferative DR 
abnormal blood vessels grow in the area of the retina. 
Adapted from https://www.gulfcoasteyecare.com/conditions/diabetic-disease-tampa-fl/ 
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Proliferative Diabetic Retinopathy (PDR) is characterized by vasculopathy 
associated with abnormal angiogenesis and expansion of extracellular matrix (ECM) 
resulting in the outgrowth of FibroVascular Membranes (FVM) at the vitreoretinal 
interface. The formation of this fibrovascular tissue results in severe complications 
such as vitreous hemorrhage and traction retinal detachment (Abhary et al., 2009; El-
Asrar et al., 2013). Angiogenesis is a multistep process requiring the degradation of the 
basement membranes and Extracellular Cellular Matrix (ECM), endothelial cell 
migration, endothelial cell proliferation and capillary tube formation.  
Vision loss may result from several mechanisms. Central vision may be impaired by 
macular edema or capillary non-perfusion. New blood vessels of PDR and contraction 
of the accompanying fibrous tissue can distort the retina and lead to tractional retinal 
detachment, producing severe and often irreversible vision loss. In addition, the new 
blood vessels may bleed, adding to the further complication of pre-retinal or vitreous 
hemorrhage (Fong et al., 2004, Ozturk et al., 2009). 
The assessment of Diabetic Retinopathy by a standardized stereoscopic photograph 
has been proposed to grade the complication and homogenize the phenotype 
classification. Researchers have been grading DR using the Early Treatment Diabetic 
Retinopathy Study (ETDRS) severity scale or a similar modification (Kuo et al., 2014). 
 
1.2.2.3 Pathophysiology of Diabetic Retinopathy 
Advanced glycation end products (AGEs) are generated by non-enzymatic 
glycosylation of proteins or lipids after prolonged exposure to glucose (Tamura et al., 
2003). AGEs elicit a wide variety of cellular responses including induction of growth 
factors and cytokines, adhesion molecules activity, oxidant stress, and chemotaxis. 
These pro-inflammatory responses contribute to the development of pathologies 
associated with aging, diabetes mellitus, and Alzheimer’s disease. (Hammes et al., 
2002) 
 
 Various studies have 
linking chronic hyperglycemia to vascular pathology in diabetes is the mitochondrial 
overproduction of reactive oxygen species (ROS) 
formation of AGEs, activation of protein kinase C
reductase (AR), and deliberation of active nuclear factor kB
have been correlated with
al., 2002; van den Oever et al.,
 
Figure 11. Mechanisms of hyperglycemia which are supposed to
Adapted from van den Oever et al., 2010
 
Microvascular mural cells, referred to as pericytes, provide vascular stability and 
control endothelial proliferation (Hammes 
Pericyte loss, microaneurysms, vascular basement membrane thickenin
occluded capillary formation are hallmarks of early changes in the retina of diabetic 
patients (Hammes et al., 
diabetic eye, the retina responds with either a progressive increase of 
permeability, leading to macula edema, or the formation of new vessels that finally 
proliferate into the vitreous (Hammes 
early diabetic retinopathy is unclear but seems related to the pericytic acc
toxic products such as sorbitol or advanced glycation end products (AGEs) (Hammes 
al., 2002). Pericyte loss is considered a prerequisite of microaneurysm formation, 
possibly by local weakening and subsequent outpouching of the capillary wal
pericytes also control endothelial cell proliferation, 
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the pathogeneis of proliferative diabetic retinopathy (Ozturk et al., 2009; Falcão et al., 
2010, Beltramo & Porta, 2013). 
 
 
Figure 12. Pericyte on a capillary. Pericytes are contractile cells with a “spider-like” shape found on the 
outside of the small vasculature. 
They play important roles in regulating capillary blood flow and are also responsible for maintaining 
permeability of the blood-brain barrier. Adapted from http://www.xvivo.net/illustration/pericyte-on-capillary/ 
 
The cross-talk between capillary cells as well as the role of capillary pericyte 
coverage in survival and repair of endothelial cells in the diabetic retina is of utmost 
importance. (Hammes et al., 2002) 
Diabetic maculopathy is characterized by hyperpermeability of retinal blood 
vessels and subsequent formation of macular edema and hard exudates. The increase 
in retinal vascular permeability occurs both diffusely and in focal regions (Sugimoto et 
al., 2013). The blood-retinal barrier (BRB) isolates the retina from the bloodstream, 
establishing a favorable environment with the regulation of ionic balance, nutrient 
availability, and blockage of potentially toxic molecules that allows for optimal retinal 
function (Sugimoto et al., 2013, Falcão et al., 2010). Disruption of this barrier is an 
important feature of diabetic retinopathy) (Figure 13).  
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Figure 13. Pathogenesis of diabetic retinopathy. Schematic overview of the effects of chronic 
hyperglycemia and its implications in cellular damage. 
AGE: Advanced Glycation End Products. ROS: Reactive Oxygen Species. BRB: Blood Retinal Barrier. Adapted 
from Falcão et al., 2010 
 
Diabetic Retinopathy also displays all microscopic signs of inflammation such as 
vasodilatation, altered flow, fluid exudation and leukocyte migration. Alterations in 
serum or vitreous levels of many inflammatory cytokines like IL-6, IL-8, IL-10, and VEGF 
also supports the role of inflammation in DR (Ozturk et al., 2009) 
 
1.2.2.4 Candidate Genes for Diabetic Retinopathy 
Several candidate gene association studies have reported promising genes but few 
of them have been replicated, and the few positive findings show only weak genetic 
associations (Kuo et al., 2014). However, several genes including AGE, VEGF and 
AKR1B1 among others have been considered to be associated with the risk of 
developing Diabetic Retinopathy (Tang et al., 2013).  
It is established that AGE and its receptor AGER contribute to diabetic complications 
through a mechanism involving direct tissue damage (Tang et al., 2013) and this effect 
seems linked to glycosylated hemoglobin levels (Goldin et al., 2006). AKR1B1 is the first 
and rate limiting enzyme of the polyol pathway and has been linked to diabetes-
specific tissue complications in some ethnic groups (Abhary et al., 2009). Other 
candidate genes such as ACE, MTHFR, SLC2A1 and APOE have been found associated 
with Diabetic Retinopathy, although not reproducibly, which may be attributed to 
small sample sizes or methodological limitations (Warpeha & Chakravarthy, 2002; 
 17 
 
Abhary et al., 2009; Tang et al., 2013). Vascular endothelial growth factor (VEGF) is 
linked to the neovascularization and vascular leakage process in proliferative 
retinopathy and various polymorphisms have been reported in different populations 
(Warpeha & Chakravarthy, 2002; Abhary et al.,2009; El-Asrar et al., 2013; Tang et al., 
2013). It is the major angiogenic factor and has been established as a survival factor in 
retinal capillary endothelium. VEGF and pericytes have complementary roles in 
promoting endothelial cell survival. 
 
1.2.2.5 Treatment and Management 
Despite recent improvements in vitreous surgical techniques, panretinal 
photocoagulation, and antivascular endothelial growth factor drugs, the prognosis for 
patients with PDR is still poor, especially for those with advanced PDR at the 
proliferative stage. It is therefore necessary to develop better diagnosis and treatment 
techniques based on the exact pathogenesis of fibrovascular membrane formation 
(Yamaji et al., 2008). 
Considerable effort has been invested recently to develop agents that block the 
formation of new blood vessels. For example, bevacizumab, a selective VEGF inhibitor, 
was recently found to be effective in the regression of retinal and iris 
neovascularization secondary to PDR, but because of its cytostatic property, its effect 
may be limited to established vasculature. Therefore, it has become apparent that 
targeted destruction of the established vasculature is another avenue for therapeutic 
opportunities (Yamaji et al., 2008). 
 
1.2.3 Genetics of Complex Diseases 
Determining the genetic basis of human diseases is one of the major research 
areas in medical science (Wang et al., 2013), but despite significant progress of 
Genome-Wide Association Studies (GWAS) in the identification of a large number of 
new genetic loci that contribute to complex traits, only a small fraction of the observed 
heritability is explained by the confirmed, genome wide-significant, common variants 
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(Rabbani et al., 2014; Manolio, 2009; Koeleman et al., 2013; Frazer et al., 2009; Tang et 
al., 2013). This has forced reconsideration of the degree of genetic heterogeneity and 
the role of genetics in the pathogenesis of complex traits (Doria, 2010; Frazer et al., 
2009).
 
Although advances in the knowledge of the genetic architecture of complex 
traits has grown over the past years we still have a limited understanding of the 
number of genetic variants that influence a trait, their allele frequencies, effect sizes 
and modes of interactions (Frazer et al., 2009).  
Recent studies
 
demonstrated that the heritability estimation is improved by using 
all genome-wide Single Nucleotide Polymorphisms (SNPs) instead of using only the 
significant variants (Kiezun et al., 2012; Lohmueller et al., 2013; Yi, 2010). Common 
genetic variation account for a non-negligible but modest proportion of inherited risk, 
leading to the suggestion that low frequency and rare genetic variants may contribute 
substantially to the genetic burden underlying common and complex disease 
(Lohmueller et al., 2013; Marth et al., 2011; Morris et al., 2012; Estrada et al., 2014; 
Panoutsopoulou et al., 2013; Marian, 2012) (Figure 14). The allelic architecture of 
complex traits is thus likely to be the combination of multiple common frequency and 
rare variants (Panoutsopoulou, 2013).
 
 
 
Figure 14 Spectrum of Disease Allele Effects. 
Disease associations are often conceptualized in two dimensions: allele frequency and effect size. Highly 
penetrant alleles for Mendelian disorders are extremely rare with large effect sizes (upper left), while most 
GWAS findings are associations of common SNPs with small effect sizes (lower right). The bulk of discovered 
genetic associations lie on the diagonal denoted by the dashed line. Adapted from Bush and Moore, 2012. 
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The selection of genetic markers investigated in most Genome Wide Association 
Studies (GWAS) has been based on the “common disease, common variant” hypothesis 
(Manolio, 2009). These studies are designed to provide a survey of common variations 
of minor allele frequencies (MAFs) >0.05 (Panoutsopoulou et al., 2013). SNP arrays 
provide a picture of genome-wide polymorphisms in many individuals; but inevitably 
suffer from ascertainment biases favoring SNPs that are common in the populations 
for variant discovery (Wang et al., 2013; Rabbani et al., 2014; Panoutsopoulou et al., 
2013). Gene sequencing methods provide a more accurate and complete perspective 
with respect to all polymorphisms in target regions in which low frequency 
(0.01<MAF<0.05) and rare (MAF<0.01) variants are assessed (Panoutsopoulou et al., 
2013). As a result, the field is now shifting toward the study of low frequency variants 
under the hypothesis of “common disease, rare variant,” this is, multiple rare variants 
with large effect size are in some cases the main determinants of the complex disease 
genetic risk (Marian, 2012; Eichler, et al., 2010).  
Whole Exome Sequencing, an approach in which all exons of protein coding genes 
are sequenced, shifts this focus from common to rare variants (Koeleman et al., 2013; 
Ng et al., 2010) and explores the extent to which rare alleles explain the heritability of 
complex diseases and health related traits. These studies enable the unbiased 
discovery of coding variations for subsequent association testing for complex traits 
(Kiezun et al., 2012) but have been underpowered and over 10000 exomes are 
required to achieve statistical power in order to robustly detect associations. Thus 
tremendous effort has been devoted to the development of tools for variant analysis 
in the process of quality control, alignment, variant identification, and downstream 
association studies (Wang et al., 2013; Wu et al., 2014). 
Exome sequencing data contain an abundance of rare coding variation and 
indicates that a large fraction of this variation is functional. There are many more rare 
variants than common ones and sequencing additional samples continues to uncover 
additional rare variants. This relative excess can be attributed to recent population 
expansion but is also likely to be due to purifying selection (Kiezun et al., 2012). Rare 
variation is enriched for evolutionary deleterious and thus functional variants and the 
proportion of non-synonymous variants is higher among rare than among common 
variants (Kiezun et al., 2012). Common variants are ancient and frequently present in 
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all human populations whereas rare variants are likely to be population specific, having 
originated from founder effects 10 to 20 generations ago. Thus, rare variants that are 
associated with complex phenotypes are likely to have effect sizes larger than those of 
common variants (Frazer et al., 2009). As it is expected that many rare variants will 
have a very restricted geographic distribution, matching of case and control ancestries 
is important (Do et al., 2012).  
 
1.2.3.1 Assessing rare coding variation 
Genetic association studies are sensitive and may detect minor susceptibility 
genes contributing less than 5% of the total genetic contribution to a disease (Tang et 
al., 2013). The approach used for this type of analysis is based on comparing the 
frequency of the allele studied in unrelated patients with matched controls. If the 
allele appears significantly more frequent in patients then in controls, then it is 
considered to be associated with the disease (Tang et al., 2013). Single nucleotide 
polymorphisms (SNPs) are the most important genetic markers for genetic association 
analysis, due to the abundance of SNPs covering the entire human genome at a high 
density (Tang et al., 2013).  
Candidate gene Association Analysis use candidate genes of a known sequence 
and location that are considered to be involved in the disease pathology. However 
approaches based on prior hypothesis have a limited power to detect novel genetic 
variants. Instead, a non-prior hypothesis is a more powerful approach for identifying 
gene association with a disease by screening the whole human genome or exome 
(Tang et al., 2013). 
 
1.2.4. Next Generation Sequencing Technologies 
In the 1970s, Sanger and colleagues and Maxam and Gilbert developed methods to 
sequence DNA by chain termination and fragmentation techniques, respectively (van 
Dijk et al., 2014). A growing demand for increased throughput led to laboratory 
automation and process parallelization which stimulated the development and 
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commercialization of next-generation sequencing (NGS) technologies (van Dijk et al., 
2014) (Figure 15). These new sequencing methods shared three major improvements: 
1) instead of requiring bacterial cloning of DNA fragments they relied on the 
preparation of NGS libraries in a cell free system; 2) instead of hundreds, thousands to 
many millions of sequencing reactions were produced in parallel; 3) the sequencing 
output was directly detected without the need for electrophoresis; base interrogation 
was performed cyclically and in parallel (van Dijk et al., 2014). The enormous numbers 
of reads generated by NGS enabled the sequencing of entire genomes at an 
unprecedented speed. However, a drawback of NGS technologies was their relatively 
short reads. (van Dijk et al., 2014) 
 
The first NGS technology to be released in 2005 was the pyrosequencing method of 
454 Life Sciences, which is now Roche. A year later, the Solexa/Illumina sequencing 
platform was commercialized. Illumina later acquired Solexa, in 2007. The third 
technology to be released was Sequencing by Oligo Ligation Detection (SOLiD) by 
Applied Biosystems, now Life Technologies, in 2007. In 2010, Ion Torrent, Life 
Technologies released the Personal Genome Machine (PGM) and then the Ion Proton. 
This system was developed by Jonathan Rothberg, the founder of 454, and resembled 
the 454 system. An important difference was that the Ion Torrent technology used 
semiconductor technology and did not rely on the optical detection of incorporated 
nucleotides using fluorescence and camera scanning. This resulted in higher speed, 
lower cost, and smaller instrument size.  
 
 
Figure 15. Next Generation Sequencing Technologies: 
Roche, 454 Technology - GS-FLX Titanium and GS-FLX+, Illumina Technology - HiSeq 2000/2500 and MiSeq 
and Ion Torrent technology - PGM and Ion Proton. Adapted from 
http://www.macrogen.com/por/service_ngs01.html 
 22 
 
 
Other NGS methods have been developed, such as Qiagen intelligent biosystems 
sequencing-by-synthesis and a single molecule detection system by Helicos 
BioSciences. In the latter, the template DNA is not amplified before sequencing, which 
places this method at the interface between NGS and the so called third-generation 
sequencing technologies (van Dijk et al., 2014). The leader in the third-generation 
sequencing field is currently Pacific Biosciences (PacBio). The long reads makes this 
technology ideal for the completion of de novo genome assemblies. It is based on the 
detection of natural DNA synthesis by a single DNA polymerase in which incorporation 
of phosphate labelled nucleotides leads to base specific fluorescence, detected in real 
time. Other promising technologies are starting to appear. An example is Nanopore 
sequencing, which is based on the transit of a DNA molecule through a pore while the 
sequence is read out through the effect on an electric current or optical signal. 
Nanopore is considered a third-generation technology because it enables the 
sequencing of single molecules in real time. A major advantage is direct sequencing of 
DNA or RNA molecules without the need for library preparation or sequencing 
reagents (van Dijk et al., 2014). It should be noted that the development of NGS has 
made huge demands on bioinformatics tools for data analysis and management. (van 
Dijk et al., 2014) 
 
The advent of massively parallel sequencing technologies has transformed the field 
of human genetics and substantially reduced the cost of sequencing large genomic 
regions relative to the traditional Sanger sequencing (Wang et al., 2013; Frazer et al., 
2009). Researchers are now capable of investigating variants from a wide range of 
allelic spectrum, including de novo mutations, variants that are too rare for inclusion 
on microarrays and higher-level structural variants. There are two unbiased 
sequencing approaches for detecting genetic variation within an individual: whole 
genome sequencing and whole exome sequencing (Gilissen et al., 2011). At this time it 
is still financially impractical, for most laboratories, to perform whole-genome 
sequencing of a large number of samples and at a sufficiently high coverage as to 
present valid large-scale genetic association studies of complex traits, such as Type 2 
Diabetes and its complications.  
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1.2.4.1 Whole Exome Sequencing 
As referred, sequencing studies are emerging as a popular approach to test for 
association of rare coding variants with complex phenotypes under the assumption 
that multiple rare variants constitute the driving force for the trait of interest (Kiezun 
et al., 2012; Do et al., 2012)  
New technologies such as Exome Sequencing, are needed to identify low frequency 
(less than 5%) or rare (less than 0.5%) variants having larger effect sizes that could 
potentially explain part of the “missing heritability” (Lyssenko & Laakso 2013; Manolio 
2009). It enables more accurate and complete variant discovery, assuming that the risk 
variant is exonic and allow for, in theory, the direct association between phenotype 
and causal variant (Wang et al., 2013). The exome representing approximately 1% of 
the human genome comprises about 30 million base pairs (Ng et al., 2010) and 
accounts for about 85% of mutations identified in Mendelian diseases (Rabbani et al., 
2014; Ng et al., 2010; Gilissen et al., 2011). Developments in high throughput sequence 
capture methods have made exome sequencing an attractive and practical approach 
for the investigation of coding variation (Wang et al., 2013; Ng et al., 2010; Do et al., 
2012) as it provides the means to explore the interpretable part of the genome (Kiezun 
et al., 2012). Alternative strategies can add the regulatory and 3’ untranslated regions 
and other functionally annotated regions of interest such as miRNA genes and various 
noncoding RNAs (Life Technologies Bulletin, 2012). 
 
1.2.5. Study Objective 
The overall aim of this study is to search and identify candidate genetic markers 
that might explain the excess risk associated to the onset of Diabetic Retinopathy. The 
genetic factors for Diabetic Retinopathy remain to be established and although 
promising genes have been reported in various genetic studies, very few have been 
replicated and even those, show only weak associations to the disease. The “common 
disease, common variant” hypothesis has been the preferred approach in the past, but 
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the search for genetic markers underlying the onset of common and complex diseases, 
and their complications, has been shifting towards the “common disease, rare variant” 
hypothesis. Although more recent and still in early stages, this has been the main 
objective of many candidate genetic marker studies: to understand the importance of 
rare variants or multiple rare variant accumulation and their relation to the onset, 
development and pathological progression of the complication. 
 
To reach this objective and contribute to the knowledge of which genetic factors 
may have an important role in this microvascular complication we will perform the 
Whole Exome Sequencing (WES) of 40 Type 2 Diabetes diagnosed Portuguese patient 
samples. Of these, 24 patients have Diabetic Retinopathy and 16 have not been 
diagnosed with Diabetic Retinopathy. The identification of rare and common variants 
will be pursued by using different bioinformatics and statistical tools in a case-control 
study. The rare variants will be searched by a gene burden test approach and so the 
outcome will be a list of biologically relevant genes whereas for the common variants, 
association tests will be applied. 
One of the main goals of this line of research is the ability to perform early 
diagnosis and apply the correct and appropriate management procedures in order to 
delay or prevent the outcome of Diabetic Retinopathy. We expect this study will bring 
forth new genetic markers that, by joining large-scale sequencing data and phenotypic 
information related to the absence, presence and severity of DR, will improve the 
treatment and thus visual health of the T2D patients.  
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Chapter 2 
Materials and Methods 
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2. Materials and Methods 
The experimental approach to this study involved Whole Exome Sequencing 
(WES) of the 40 Type 2 Diabetes (T2D) patients. Various tasks had to be addressed: 
DNA extraction and quality control, exome library preparation, template amplification 
and sequencing-by-synthesis with the next-generation sequencing platform Ion 
Proton. The sequencing, quality filtering, analysis and identification of variants were 
performed with proprietary Ion Torrent software. Bioinformatics tools, developed at 
Genoinseq, then filtered, annotated and prioritized the variants. The interpretation of 
the list of genetic variants, their biological relevance and possible association to 
Diabetic Retinopathy was further assessed and the variants encountered were 
validated by genotyping thus concluding the tasks proposed for this study. 
 
2.1 Patients Characterization 
Blood samples from 40 Portuguese patients diagnosed with Type 2 Diabetes were 
used in this study. The samples, collected from the Endocrinology Unit of the Hospital 
Center of the University of Coimbra, were object of the DIAMARKER subproject: 
Genetic susceptibility for multi-systemic complications in Diabetes Type 2: New 
biomarkers for diagnostic and therapeutic monitoring from the Do-IT - Development 
and Operation of Translational Research project. One of the aims of this project was 
the development of solutions for diagnosis, prognosis and treatment of cancer, 
neurodegenerative diseases and diabetes. The object of this thesis was included in the 
objectives of the overall project to search for genetic markers for Type 2 Diabetes and 
its complications. 
All 40 diabetic patients were characterized for various parameters: age, sex, 
glycated hemoglobin levels (HbA1c), retinopathy grade measured according to the 
Early Treatment Diabetic Retinopathy (ETDR) values and diabetes duration (Table I in 
Appendix). Of these, 24 patients (Cases) were diagnosed with Diabetic Retinopathy 
(ETDR value ≥ 20) and 16 patients (Controls) without Diabetic Retinopathy (ETDR value 
< 20) according to the clinical diagnosis of diabetic retinopathy. Twenty individuals not 
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diagnosed with Type 2 Diabetes, by the same parameters, were selected as second 
Control group for validation procedures. Moreover, twenty other samples of the 
Portuguese population, which exomes had been previously sequenced at Genoinseq, 
were also used for validation of the sequencing technology platform and the frequency 
of the variants encountered. All participants signed an informed consent. 
 
2.2 DNA Extraction and Quality Control 
2.2.1 DNA Extraction 
Blood samples contain enzyme inhibitors and common anticoagulants such as 
heparin and EDTA that can interfere with the sequencing downstream assays. Thus, 
the DNA isolation procedure has to provide high-quality, inhibitor-free DNA.  
DNA was extracted from the blood samples using DNeasy Blood and Tissue Kit 
(Qiagen, Hilden), with minor modifications to the manufacturer’s instructions to 
ensure the best DNA yield and purity.  
Briefly, samples were processed using a lysis buffer containing a detergent, for 
the disruption of cellular membranes and proteinase K, for the digestion of protein 
cellular components. Buffering conditions were adjusted to provide optimal DNA-
binding and the lysate was loaded onto the DNeasy Mini spin column. During 
centrifugation, DNA was selectively bound to the DNeasy membrane as contaminants 
passed through. Remaining contaminants and enzyme inhibitors were removed in two 
efficient wash steps and the DNA eluted in 100µl Tris-EDTA buffer.  
 
2.2.2 DNA Quality Control 
DNA qualification procedures consist of both the quantification of double 
stranded DNA (dsDNA) and the assessment of its suitability, purity and integrity, for 
downstream applications. To assess the purity and presence of contaminants, 2µl of 
each DNA sample was applied to the Nanodrop ND-1000 spectrophotometer 
(ThermoFischer Scientific, Germany) and the DNA concentration was determined by 
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measuring the absorbance at 260 nm. The ratio of the readings at 260 nm and 280 nm 
(A260/A280) on the spectrophotometer provided an estimate of DNA purity with respect 
to contaminants that absorb UV light, such as protein. Pure DNA has an A260/A280 ratio 
of 1.7–1.9. If, the samples did not reach the minimum acceptance values for A260/A280 
and A260/A230 ratios, the DNA samples were subjected to a standard isopropanol 
purification method (Table II in Appendix). 
The integrity and size of the genomic DNA samples was assessed by running 
approximately 50ng of DNA against a 1 Kb molecular marker, NZY DNA Ladder III 
(NzyTech, Lisboa, Portugal) on a 0.8%, TAE 1x, agarose gel in TAE 1x, to which we 
applied a 90V current for 30 min. The ethidium bromide stained agarose gel was 
visualized under ultraviolet light with the Molecular Imager Gel Doc XR System (Biorad, 
California, USA). This procedure is not highly accurate since large DNA molecules 
migrating through a gel will essentially move together in a size-independent manner 
however, it provides sufficient information in terms of integrity (DNA size range) and 
purity as RNA contamination runs as a diffuse smear at the bottom of the gel.  
Fluorometry measurements allow the specific quantification of double stranded 
DNA (dsDNA) by the use of a fluorescent dye. The High Sensitivity PicoGreen Assay 
(Invitrogen, LifeTechnologies, USA) is highly sensitive and can detect as little as 20 pg 
of dsDNA in a 200µl assay. DNA standards and samples were mixed with the 
fluorochrome from the kit, according to standard manufacturers’ recommendations 
and measured on the GeminiEM Microplate fluorometry instrument (Molecular 
Devices, Sunnyvale, CA). Sample measurements were then compared to the standards 
to determine DNA concentration. This assay is optimized to minimize the fluorescence 
contributions of RNA and ssDNA, such that dsDNA can be accurately quantified in the 
presence of equimolar concentrations of ssDNA and RNA with minimal effect on the 
quantitative results (Simbolo et al., 2013).  
Samples were considered complient if pure (A260/A280 and A260/A230 ratios above 
1.7), integrate, inhibitor free and had a concentration > 10ng/µl. 
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2.3 Whole Exome Sequencing 
Figure 16 illustrates the Ion Proton Exome Sequencing workflow which comprises 4 
basic steps: 1) Library Construction; 2) Template Preparation; 3) Sequencing and 4) 
Data Analysis. 
 
Figure 16. Basic workflow for Ion Proton Exome Sequencing: 
Construct Library, Prepare Template, Run Sequence and Analyze Data. Adapted from 
http://dna.macrogen.com/eng/support/event/event_view.jsp?board_number=20187 
 
2.3.1 Ion AmpliSeq Exome Library Preparation Protocol 
Once the high quality DNA sample was purified, an exome library for each 
sample was prepared from 75ng with the Ion AmpliSeq™ Exome Library Preparation Kit 
(Life Technologies, Carlsbad, USA), according to the manufacturers’ protocols. This 
procedure amplifies target exonic regions from 10-100 ng of genomic DNA (gDNA). It 
contains 12 primer pools, in a total of approximately 294,000 primer pairs for ultra-
high multiplex PCR enrichment of the exome and is designed to create overlapping 
amplicons covering large target regions. The amplicons generated were then treated 
with FuPa Reagent to partially digest the primers and phosphorylate the amplicons. 
These were then ligated to Ion Adapters with barcodes and finally purified. The 
concentration of each Ion AmpliSeq Exome library was determined by qPCR with the 
Ion Library Quantitation Kit (Life technologies, Carlsbad, USA) (Figure 15), according to 
manufacturers’ recommendations. Exome library quality was assessed using the High 
Sensitivity DNA Kit (Agilent Technologies, Waldbronn, Germany) and the Agilent 2100 
Bioanalyzer System (Agilent Technologies, Santa Clara, USA), according to the 
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recommended manufacturers’ protocol. Proper dilutions were prepared for template 
amplification and Ion Proton Sequencing. 
 
 
Figure 17. Library Preparation by Ion AmpliSeq Exome Technology. 
Adapted from Ion AmpliSeq Exome Library Preparation Quick Guide. 
 
2.3.2 Template Preparation and Exome Sequencing by Ion Torrent 
Technology  
2.3.2.1 Clonal amplification of Templates 
For most commercially available next-generation sequencing platforms, the clonal 
amplification of each DNA fragment by emulsion PCR is necessary in order to generate 
sufficient copies of sequencing template. The presence of adapter sequences enables 
selective clonal amplification of the library molecules (Figure 18, A). Furthermore, the 
adapter sequence also contains a docking site for the platform-specific sequencing 
primers (Life Technologies, 2012). 
 
 
Figure 18. Clonal Amplification of templates. 
A. Clonal amplification of each DNA fragment. B. Ion One Touch 2 System. Adapted from Ion PI Template 
OT2 200Kit v2 protocol. 
A 
B 
 31 
 
 
Template preparation was performed on the Ion OneTouch2 System (Figure 18, B) 
according to manufacturer’s instructions and the Ion PI Template OT2 200Kit v2 
protocol. 
 
2.3.2.2 Chip Preparation and Loading 
After clonal amplification of the DNA fragments on the Ion Sphere Particles (ISPs), 
the enrichment of the template-positive ISPs, ion sphere particles that have amplified 
DNA, and performance of the ISP quality control, the enriched particles were prepared 
for loading on the PI chip, according to the manufacturers' protocol (Figure 19). The 
sequencing runs were performed with 2 exome libraries, each with a unique Molecular 
IDentifier (MID). (Exome vs IonXpress Barcode - Table III in Appendix) 
 
 
Figure 19. Chip Preparation and loading. 
Ion PI chip loading with template-positive ISPs. B. Ion PI chip fitting into chip clamp. C. Ion Proton 
Sequencer. Adapted from Ion PI Sequencing 200 Kit v2 protocol. 
 
Exomes were sequenced on the Ion Proton System and Ion PI chipv2 following 
manufacturer’s instructions and the Ion PI Sequencing 200Kit v2 protocol. 
 
2.3.2.3 Exome Sequencing 
The incorporation of a deoxyribonucleotide triphosphate (dNTP) into a growing 
DNA strand involves the formation of a covalent bond and the release of 
pyrophosphate and a positively charged hydrogen ion. Ion semiconductor sequencing 
A B C 
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exploits these facts by determining if a hydrogen ion is released upon providing a 
single species of dNTP to the reaction (Life Technologies,
 
2012). 
Micro wells on a semiconductor chip each containing many copies of one single-
stranded template DNA molecule and DNA polymerase are sequentially flooded with 
unmodified dATPs, dCTPs, dGTPs or dTTPs. The hydrogen ion that is released in the 
reaction changes the pH of the solution, which is detected by an ion-sensitive field-
effect transistor (ISFET) used for measuring ion concentrations in solution. When the 
H
+
 concentration changes, the pH is altered and the current through the transistor 
changes accordingly (Figure 20). 
The series of electrical pulses transmitted from the chip to a computer is 
translated into a DNA sequence, with no intermediate signal conversion required. 
Because nucleotide incorporation events are measured directly by electronics, the use 
of labeled nucleotides and optical measurements are avoided. Signal processing and 
DNA assembly is then carried out in appropriate software
 
(Life Technologies,
 
2012). 
In this study, twenty sequencing runs were performed for a total of 40 exomes.  
 
 
Figure 20. Sensor, well and chip architecture and Data collection. 
A simplified drawing of a well, a bead containing DNA template, and the underlying sensor and electronics. 
Protons (H
+
) are released when nucleotides (dNTP) are incorporated on the growing DNA strands, changing 
the pH of the well (ΔpH). This induces a change in surface potential of the metal-oxide-sensing layer, and a 
change in potential (ΔV) of the source terminal of the underlying field-effect transistor. Nucleotide 
incorporation signal from an individual sensor well; the arrow indicates start of incorporation event, with 
the physical model (red line) and background corrected data (blue line) shown. Adapted from, Rothberg et 
al., 2011. 
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2.4 Bioinformatics Analysis 
Next-generation sequencing instruments sequence millions of short DNA 
fragments in parallel. The data generated requires sophisticated computation and 
bioinformatics tools that become more and more crucial in the analysis and 
interpretation of sequencing data (Figure 21). Many alignment methods and variant 
callers have been developed and used to create complex pipelines. For the Ion Proton, 
the most efficient mapping and variant calling software are the ones developed by the 
manufacturers, as previously determined at Genoinseq (Life Technologies,
 
2012). 
 
 
Figure 21. Data Collection, Signal Processing and Base Calling. 
Files generated by the Ion Torrent Suite: SFF, FASTQ, BAM and VCF files are shown. Adapted from Life 
technologies, 2012. 
 
2.4.1 Signal Processing, Base Calling and Mapping of exome sequenced 
data  
After a sequencing run is complete, the main data analysis step of the software 
included base calling and mapping of the sequence data to a reference genome (Do et 
al., 2012). 
The raw data obtained by Ion Proton Sequencing System was processed on the Ion 
Proton sequencer and further transferred to the Proton Torrent Server, for read 
mapping and variant calling. (Figure 22) 
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Figure 22. Bioinformatics Processing of sequenced raw data. 
Adapted from Life Technologies, 2012. 
 
For each of the 40 sequenced exomes, the Ion Proton adaptor sequences and low 
quality bases were trimmed using Torrent Suite software (Life Technologies, Carlsbad, 
CA, USA). The filtered reads were then mapped against the human reference genome 
hg19, using the TMAP version 4.0.6 (Life Technologies, Carlsbad, CA, USA). The 
resulting sequence alignment was stored in a Binary Alignment Map (BAM) file (Li et 
al., 2009). 
For sample identification control, the number of reads mapped on the Y 
chromosome were counted using SAMTools (Li et al., 2009) and divided by the number 
of total mapped reads thereby creating a ratio to determine the sample sex. This 
informatics sex was then compared to the subject sex. All samples passed this sample 
identification control. 
 
2.4.2 Variant calling 
The Variant Caller identifies variant sites where the aligned sequences deviate 
from the reference sequences at known positions. Variant calling for homozygous or 
heterozygous SNPs and small or large insertions and deletions (indels) was the next 
automated step in the data analysis process and was performed by Torrent Variant 
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Caller plugin version 4.0 (Life Technologies, Carlsbad, CA, USA), with the optimized 
parameters for exome sequencing as recommended for Ion AmpliSeq™ Exome Kit (Life 
Technologies, Carlsbad, CA, USA).  
Torrent Variant Caller (TVC) is a genetic variant caller for Ion Torrent™ Sequencing 
platforms, and is specially optimized to exploit the underlying flow signal information 
in the statistical model to evaluate variants. It is designed to call single-nucleotide 
polymorphisms (SNPs), multi-nucleotide polymorphisms (MNPs), insertions, deletions, 
and block substitutions. Basically it: 1) finds all positions with any evidence for a 
variant, 2) focuses on these positions and evaluates if there is enough evidence for a 
SNP or indel call and 3) filters the candidates based on key parameters (strand bias, 
enough coverage, known error prone position) (Life Technologies,
 
2012).  
Interactive tables of identified variants were able to be visualized and evaluated 
using Broad Institute's Integrative Genomics Viewer (IGV) (Life Technologies,
 
2012)
 
(Figure 23). Variants that passed all the set filters were reported to a single output 
variant call format (VCF) file (Life Technologies,
 
2012; Danecek et al., 2011). Further 
steps involved filtering and annotation to reduce variant sites to a set of genes with 
possible function and activity. 
 
 
Figure 23. An example of Integrative Genomics Viewer (IGV) interactive table. 
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In our study, all variants with less than 10X coverage were discarded. In addition, 
overall variant positions from the 40 exomes were considered and integrated 
altogether using VCFTools (Danecek et al., 2011). For all positions, the homozygous 
equal to the reference genome positions were further evaluated since no information 
about these genotypes was reported in the variant calling file generated. A script 
developed at Genoinseq was used to detect reference genotypes when the altered 
allele frequencies in the mapping file were lower than 5%. If the altered allele 
frequency was higher than 5%, the genotype was considered undetermined. 
The genotypes were then recalled based on the altered allele frequency using an 
in-house script. Altered homozygous genotypes were assigned for altered allele 
frequencies (aaf) higher than 0.8 and heterozygous for frequencies between 0.2 and 
0.8. 
 
Functional consequences of variants can be predicted by examining the effects of 
amino-acid changes using comparative sequence and protein structure analyses. Many 
computational prediction and conservation methods are available (Kiezun et al., 2012; 
Do et al., 2012). According to their impact on protein-coding transcripts, annotation 
tools can identify single nucleotide variants that result in synonymous, missense, 
nonsense, splice site alterations or read-through alterations. Indels are typically 
annotated according to whether or not they result in frameshift (Do et al., 2012). 
These annotation tools also assign each variant a score, based on analysis of protein 
structure or evolutionary conservation to separate variants with little functional 
impact from those more likely to damage protein function (Do et al., 2012). Some 
variants might have more than one annotation resulting from various overlapping 
transcripts. These annotation conflicts are resolved by focusing on: 1) only canonical 
transcripts for each gene (RefSeqGene or Ensembl), 2) the longest transcript in each 
gene or 3) the most deleterious prediction from all available transcripts (Do et al., 
2012). The accuracy of those methods is approximately 80% and is likely highest for 
rare variants. Truly functional variants are most likely deleterious and are kept at low 
frequencies by purifying selection and so, common variants are most likely neutral and 
non-functional. Therefore using prediction methods enriches for functional variants 
and thereby boosts the power of association tests (Kiezun et al., 2012). 
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In our study and to predict the impact of genetic variation on protein coding 
transcripts, Variant Effect Predictor (VEP) software was used (McLaren et al., 2010). 
The transcripts were obtained from Ensemble, version GRCh37 (Cunningham et al., 
2015). The VEP results were then used by the Gemini framework (Paila et al., 2013) to 
annotate the variants against a comprehensive set of genomic annotation files 
including: dbSNP (Sherry et al., 2001), ENCODE (Dunham et al., 2012), ClinVar 
(Landrum et al., 2014), 1000 Genomes (McVean et al., 2012), the Exome Sequencing 
Project (NHLB1), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 
2014; Kanehisa et al., 2000), Genomic Evolutionary Rate Profiling (GERP) (Cooper et al., 
2005), and Human Protein Reference Database (HPRD) (Prasad et al., 2009). Finally, 
Gemini saved all information related to impact and annotation prediction in a 
database for further analysis. Furthermore, to detect relatedness between samples the 
Gemini framework performed pair-wise genetic distance tests. 
 
2.5 Statistic Analysis 
The two populations, cases and controls, were characterized for age, sex, disease 
duration and glycated hemoglobin levels (HbA1c) using the IBM SPSS software, Version 
20.0 (Armonk, NY: IBM Corp.). The variants were tested using the Pearson Ҳ2 test for 
the qualitative variables (sex and presence vs. absence of DR) and the Fisher exact test 
for the quantitative variables (age, HbA1c levels and disease duration). 
Statistical analyses of both common and rare variants were performed using 
different approaches. The analyses of rare variants require statistical methods that are 
fundamentally different from association statistics used for testing common variants. 
Rare variants have to be combined in a gene (or pathway) for an association test to 
reach sufficient power (Kiezun et al., 2012) while for common variants, traditional 
regression-based association tests are normally applied (Kiezun et al., 2012).  
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2.5.1 Identification of common variants 
The common variant approach consisted in the prioritization of common variants 
using the Pearson Ҳ
2
 test or the Fisher exact test to detect the ones that had significant 
genotype differences between cases and controls (univariate analysis). The variants 
with a p-value lower than 0.05 were then tested in a binary logistic regression model 
for adjustment to external factors like age, sex, disease duration and glycated 
hemoglobin. Adjusted odds ratios (ORs) and 95% confidence intervals were computed 
and statistically significant results were considered for p<0.05. The univariate analysis 
and logistic regression were computed with the StatsModels python module 
(http://statsmodels.sourceforge.net).  
 
2.5.2 Identification of rare variants accumulating genes 
Although every analysis of exome sequence data should start with single variant 
association tests, these are not well powered for rare variants. Because most variants 
are individually rare, achieving adequate statistical power requires a design with the 
ability to combine and evaluate groups of variants likely to have an impact on the 
function of a specific gene and to compare the distribution of these variant groupings 
to the distribution of the trait of interest (Do et al., 2012).  
The approach for rare variants identification aimed to prioritize variants using the 
EPACTS – Efficient and Parallelizable Association Container Toolbox (Kang et al., 2010), 
by performing a gene-wise burden test. We used a package that enables the 
implementation of a variety of burden tests, (http://genome.sph.umich.edu/wiki/EPACTS) 
(Kang et al., 2010; Do et al., 2012). 
 
The Gemini framework was used to select variants that passed the Hardy-
Weinberg equilibrium (HWE ≥ 0.001), with a call rate higher than 80%, a minor allele 
frequency lower than 1% (either in the ESP project or 1000 Genomes project), a minor 
allele frequency in our population lower than 5% and that were non-synonymous or 
present in splice site regions and thus predicted to be of medium (MED) or high (HIGH) 
severity. All indel variants were excluded. The selected variants were saved in the 
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Variant Call Format (VCF) file. These variants were grouped by gene using EPACTS. A 
binary (cases vs. controls) and a quantitative gene-wise burden emmaxVT test (cases 
adjusted to ETDR vs. controls) was then performed to select new candidate genes for 
the DR complication.  
 
2.6 Genetic Variant Validation 
In some rare cases, exome sequencing of a single large sample will be sufficient to 
demonstrate association of encountered variants with a disease. More often it is 
necessary to examine the most promising variants in additional samples (Do et al., 
2012). Genotyping validation provides an additional measure of call set quality 
independent of the population genetics statistics (Kiezun et al., 2012) and the 
genotyping assay should include sites at various allele frequencies, common and rare, 
but especially at low frequencies (~1%) (Kiezun et al., 2012).  
 
For this study we considered various validation procedures: 1) validation of the 
sequencing technology by genotyping 8 of the 40 exomes by Illumina microarray with 
the HumanOmniExpressExome Protocol (Illumina, San Diego, CA, USA); 2) comparison 
of the MAF for each common or rare variant in 20 sequenced exomes unrelated to the 
study in question; 3) validation of the common variants, by Sanger sequencing, of 2 
homozygous and 2 heterozygous for the altered allele; 4) validation of the rare variants 
encountered by ASO-PCR genotyping; 5) confirmation that the rare variants 
encountered are in fact rare in our population by ASO-PCR genotyping of 20 non T2D 
Portuguese control samples. 
 
The eight samples used for sequencing technology validation were sent to ATLAS 
Biolabs GmbH at Berlin, Germany, to confirm the results of the Ion Proton platform.  
2.6.1 Sanger sequencing 
Sanger sequencing is a method of DNA sequencing based on the selective 
incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in 
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vitro DNA replication. This method although much less than in decades before, 
remains in wide use for smaller-scale projects, validation of Next-Generation 
sequencing results and for obtaining especially long contiguous DNA sequence reads 
(>800 nucleotides). 
To validate the results obtained for candidate common variants, we sequenced 2 
homozygous and 2 heterozygous patients for each variant that had not been validated 
by Illumina microarray technology. 
DNA was amplified for each gene region of interest with the forward and reverse 
primers represented in Table 1 and the purified fragment sent to GATC Biotech 
(Cologne, Germany) for Sanger sequencing. PCR reactions were performed for each 
sample using 1x Advantage SA PCR Buffer, 0.2 μM of each PCR primer, 0.2 mM dNTPs 
(Bioron, Ludwigshafen am Rhein, Germany), 6% DMSO (Roche Diagnostics GmbH, 
Mannheim, Germany), 1x Advantage 2 Polymerase Mix (Clontech, Mountain View, CA, 
USA), and 50ng of template DNA in a total volume of 50μl. The PCR conditions involved 
a 4 min denaturation at 94ºC, followed by 30 cycles of 94ºC for 30s, specific annealing 
temperature for 45s and 68ºC for 60s and a final extension at 68ºC for 10 min. 
Negative controls were included for all amplification reactions. Electrophoresis of the 
PCR products was undertaken on a 1% (w/v) agarose gel and the amplified fragments 
were purified using AMPure XP beads (Agencourt, Beckman Coulter, USA) according to 
manufacturer's instructions.  
Table 1. rs ID, gene and primer information for common variant validation. The gene sequence 
ensemble ID, gene direction, primer sequence and fragment size are also represented. 
rs ID Gene  
Gene sequence 
ID 
Gene 
Direction Primer Name Primer Sequence 5' - 3' 
Fragment 
Size (bp) 
rs62357156 ITGA1 
ENSG000002139
49.8 
Forward 
Strand (1) 
ITGA1_DR_F CTCAGGAGAAAGCAGTTGTG 
537 
ITGA1_DR_R CACCCATCCAACATGAAGAC 
rs2296123 PRKCQ 
ENSG000000656
75.14 
Reverse 
Strand (-1) 
PRKCQ_DR_F GTGCTCTGTCCTCCTTATAC 
355 
PRKCQ_DR_R GGTATTCGTCTTGGCATCTC 
rs80067372 TNFSF12 
ENSG000002396
97.10 
Forward 
Strand (1) 
TNFSF12_DR_F CTTCTTGGGCACATCAGGAG 
463 
TNFSF12_DR_R CTCTTCCACGCAGACTCAC 
rs10794640 NARFL 
ENSG000001032
45.13 
Reverse 
Strand (-1) 
IOP1_DR_F GTGAAGGGTGAAGGTCAGTG 
532 
IOP1_DR_R CAGGTGAATTCGACCAGTGG 
rs4434138 
STAB1 
ENSG000000103
27.10 
Forward 
Strand (1) 
STAB1_DR_F CGTCCTTGCTTCATTCCCTC 
484 
rs4234633 STAB1_DR_R CATAGAAGGTGGAGAAGTTGG 
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2.6.2 ASO-PCR Genotyping 
The increasing need for large-scale genotyping applications of single nucleotide 
polymorphisms (SNPs) in model and non-model organisms requires the development 
of low-cost technologies accessible to minimally equipped laboratories. The method 
used for validation of the rare variants encountered allows efficient discrimination of 
SNPs by allele-specific PCR with optimized PCR conditions. A common reverse (or 
forward) primer and two forward (or reverse) allele-specific primers with different tails 
amplified two allele-specific PCR products, which were visualized by agarose gel 
electrophoresis. PCR specificity was improved by the introduction of a destabilizing 
mismatch within the 3′ end of the allele-specific primers. This is a simple and 
inexpensive method for SNP detection (Gaudet et al., 2009) and was applied to 
validate the true rarity of the candidate rare variants, this is, certify if these variants 
were in fact rare or if they were a characteristic polymorphism of the Portuguese 
population.  
The ASO-PCR reactions for each rare variant validation had to be individually 
optimized. The primers used for each genotype determination are listed in Table 2. A 
pair of control primers were added to each PCR reaction to ensure that all the 
conditions for amplification were met. 
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Table 2. rs ID, gene and primer information for common variant validation. The gene sequence 
ensemble ID, gene direction, primer sequence and fragment size are also represented. 
rs ID or Pos. Gene Gene sequence ID 
Gene 
Direction Primer Name Primer Sequence 5' - 3' 
Fragment 
Size (bp) 
rs114516513 
DMXL2 
E
N
S
G
0
0
0
0
0
1
0
4
0
9
3
.1
3
 
Reverse 
Strand (-1) 
DMXL2_DR_F_T CTGATGAAAGCATTCATAGTGA 
541 DMXL2_DR_F_C CTGATGAAAGCATTCATAGTGG 
DMXL2_DR_R GTTTAGCCCACTCTCCAACC 
Chr15: 
51743890 
DMXL2_DR_F1 GTGAGAGATGAGGATTCAGG 
454 DMXL2_DR_R1_C AATGTGTCCCAGAGGCAAAC 
DMXL2_DR_R1_G AATGTGTCCCAGAGGCAAAG 
Chr15: 
51772229 
DMXL2_DR_F2 CTTCAGTAAGGATGGAACTC 
579 DMXL2_DR_R2_C CATGGATGTGATTATTTAAGTAC 
DMXL2_DR_R2_G CATGGATGTGATTATTTAAGTAG 
rs141999878 
E2F8 
E
N
S
G
0
0
0
0
0
1
2
9
1
7
3
.1
2
 
Reverse 
Strand (-1) 
E2F8_DR_F_C CTTTATTAAGAGTTACAGTATAGAG 
431 E2F8_DR_F_A CTTTATTAAGAGTTACAGTATAGAT 
E2F8_DR_R CTTCTAGGCTTACTATCTGAGG 
rs77599073 
E2F8_DR_F2_C GTTTTCTGTTTCAGGCTCCAG 
617 E2F8_DR_F2_G GTTTTCTGTTTCAGGCTCCAC 
E2F8_DR_R2 CCAACCTACCTTGATTGCTC 
rs793274 
E2F8_DR_F3_T CAGGATTTACAGCTCCCCAA 
524 E2F8_DR_F3_C CAGGATTTACAGCTCCCCAG 
E2F8_DR_R3 GTCACAGCAACTGATTGTCC 
Chr11: 
19247163 
E2F8_DR_F4_C CTTCCCCCTTTTCCTTCCAG 
402 E2F8_DR_F4_G CTTCCCCCTTTTCCTTCCAC 
E2F8_DR_R4 GTCACAGCAACTGATTGTCC 
Chr11: 
19258929 
E2F8_DR_F5_C GTGTCATAAGTTCTTAGCACG 
700 E2F8_DR_F5_T GTGTCATAAGTTCTTAGCACA 
E2F8_DR_R5 CACAGCACATCACTTCACAG 
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3. Results and Discussion 
3.1 Patient Characterization 
Our study population had forty 40 T2D patients. Twenty-four were diagnosed with 
Diabetic Retinopathy (ETDR>20) and considered Cases and sixteen had no symptoms 
of Diabetic Retinopathy (ETDR≤20) and were thus considered Controls. Table 3 
presents the characteristics and statistical analysis of the studied population. 
 
Table 3. Characteristics and statistical analysis of the study population. The population was 
analyzed for sex, age, disease duration and glycated hemoglobin (HbA1C) levels. Differences in the 
characteristics were evaluated with the Pearson Ҳ2 test for the qualitative variables and the Fisher 
exact test for the quantitative variables. SD - Standard Deviation . 
Patients DR (n=24) non-DR (n=16) t-test Ҳ
2
 
Female (n, %) 10 (41.7%) 10 (62.5%)  
 
0.197 
Male (n, %) 14 (58.3%) 6 (37.5%) 
Age (years ± SD) 63.83 ± 6.91 64.38 ± 8.32 0.824  
HbA1C (% ± SD) 9.45 ± 1.83 9.59 ± 2.94 0.846  
Diabetes duration (years ± 
SD) 
   19.21 ± 
8.41 
12.44 ± 8.03 0.015  
 
Perhaps the most important step in any exome sequencing study is the choice of 
samples to sequence (Do et al., 2012). The characteristics of the study population are a 
key component of robust allelic association studies. The desire is to eliminate all 
potential confounding as well as competing non-genetic variables in order to amplify 
the effects of genetic variants. Cases and controls should be matched, as much as 
possible, for demographics and other characteristics in order to enrich the chance of 
detecting genetic effects (Marian, 2012). 
There were no significant statistical differences between cases and controls for sex, 
age and HbA1c levels. The only parameter that was statistically significant was 
diabetes duration (p<0.05). It is known that diabetes duration is the parameter that is 
largely responsible for the development and aggravation of diabetic retinopathy (Tarr 
et al., 2013; Ola et al., 2012 and Safi et al., 2014). This finding is reflected in our study 
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population as this covariate sets the difference between presenting, or not, the 
microvascular complication.  
The characterization of all patients is thoroughly presented in Table I (in 
Appendix). 
 
Various studies have repeatedly shown that uncontrolled diabetes results in 
complications from the disease (Fong et al., 2004; Droumaguet et al., 2006). Glycated 
Hemoglobin A1c is formed through the nonenzymatic gycation of hemoglobin. In 
patients with T2D, it is used as a therapeutic target and shows a good correlation with 
the risk of developing microvascular complications (Chen et al., 2013). As so, the goal 
for people with diabetes, is a HbA1c level lower than 7%. (Fong et al., 2004; 
Droumaguet et al., 2006, Sugimoto et al., 2013, Ozturk et al., 2009). Interestingly, 5 
patients: Ex19, Ex27, Ex44, Ex45 and Ex50, suffering with T2D for 23, 19, 33, 20 and 15 
years respectively did not have Diabetic Retinopathy and revealed poorly controlled 
blood glucose levels (HbA1c>7%). On the other hand, Ex12 has had T2D for 6 years, 
revealed a controlled glucose level (HbA1c=6.3%) but suffers from Diabetic 
Retinopathy. These observations support the idea that the onset of Diabetic 
retinopathy may have a genetic cause. 
 
3.2 DNA Extraction and Quality Control 
All DNA samples extracted revealed high integrity and the absence of RNA 
contamination as can be seen in figure 24. The purity determination and quantification 
results of the all 40 DNA samples are presented in Table II (in Appendix).  
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Figure 24. Agarose gel (0.8%) electrophoresis of genomic DNA samples: 
Ex30 and Ex33 to Ex50. 1Kb, NZYDNA Molecular Marker Ladder III. The gel was stained with Ethidium 
bromide and the image presented in inverse. 
 
3.3 Ion AmpliSeq Library Preparation 
After Exome Library Preparation, quality control procedures were performed. 
Figure 25 presents an example of the expected Bioanalyzer profile with libraries 
ranging from 200 to 350bp. All 40 exomes were controlled and further validated for 
exome sequencing. 
 
 
Figure 25. Bioanalyzer profile of the amplified exome library sample Ex21. 
The size range was determined on the Agilent Bioanalyzer instrument with the Agilent High Sensitivity DNA 
kit, according to manufacturer’s instructions. The upper and lower marker peaks are identified and correctly 
assigned (green and purple numbers on the trace). The black numbers on the trace peaks represent the size 
of the fragments. 
 
30     33    34    35    36    37    38    39   40  M1Kb  41   42    43    44    45    46    47    48   49    50  
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3.4 Exome Sequencing Results 
Standards for the generation of high-quality exome sequence data are rapidly 
emerging (Do et al., 2012). A high-quality base coverage of 20x or greater in 80-95% of 
the protein-coding sequences in each genome, after removal of ambiguously mapped 
and duplicated reads, should be able to identify the vast majority of protein-coding 
variants with high specificity but because the efficiency of enrichment protocols 
exhibit great local variation, sequencing the protein coding region of each individual to 
an average depth of 60-80x is recommended (Do et al., 2012).  
 
3.4.1 Exome Sequencing Metrics 
Figure 26 presents the sequencing run report of samples Ex31 and Ex33 in the Ion 
Proton sequencing platform. In this case, nearly 100 million reads were generated with 
a mean fragment size of 193bp. 
 
 
Figure 26. Run Report for Exome Sequencing of Samples Ex31 and Ex33 with Ion Proton. 
90,989,101 reads with a mean length of 193bp were generated in a total of 17.5G bases. 
 
The obtained reads were then mapped against the human reference genome 
hg19. The mean coverage analysis metrics for all 40 samples are presented in Table 2. 
The average mapped reads, which refer to the number of reads that were mapped to 
the full reference genome, were 41.6 ± 6.3 million (mean ± standard deviation). Nearly 
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95% of the reads targeted the aimed region, providing a mean coverage of almost 
120X. 
 
Table 4. Coverage Analysis Metrics. The mapped reads refer to the number of reads that mapped 
the reference genome, the reads on target reflect the percentage of mapped reads that were 
aligned to the target region, the mean depth is the mean average target base reads coverage and 
the coverage uniformity is the percentage of target bases covered by at least 0.2x the average base 
read depth. 
Metrics Values  Mean ± Standard Deviation) 
Mapped Reads (million ± SD) 41.6 ± 6.3 
On Target (% ± SD) 94.5 ± 0.9 
Mean Depth (x ± SD) 119 ± 19 
Coverage Uniformity (% ± SD) 92.0 ± 1.3 
 
An important consideration for variant discovery is Coverage which typically 
translates into confidence in variant calling. Greater coverage increases the confidence 
in putative variants. Another parameter, Coverage Uniformity, is also important for 
exome sequencing since this minimizes the amount of sequencing needed to achieve a 
desired coverage threshold of 20x with a significant proportion of exome bases 
targeted, above 90% (Do et al., 2012; Life Technologies, 2012). This value informs 
whether the exome was uniformly covered or if there was a particular region that was 
more or less sequenced. The sequencing and coverage metric values we obtained were 
within the value range predefined by Ion Torrent for high quality exome sequencing 
with AmpliSeq. 
The coverage depth and on target % for all 40 exomes sequenced are 
represented in Figures A and B in the Appendix. 
 
3.4.2 Variant Caller Metrics 
The comparison of the sequenced exomes to the reference genome sequence 
(hg19) by the Torrent Variant Caller identified an average of 52,698 variants, per 
sample. Of these, 91.3±2.8% were Single Nucleotide Polymorphisms (SNPs), 3.3±1.8% 
were insertions, 4.8±1.7% were deletions and 0.3±0.5% were multiple nucleotide 
polymorphisms (MNPs) (Figure 27). 
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Figure 27. Representation of the median number of variant calls obtained by type. 
Single Nucleotide polymorphism (SNP), Insertion (INS), deletion (DEL), Multiple Nucleotide Polymorphism 
(MNP). 
 
3.5 Candidate Genes obtained by Rare Variant accumulation 
One of the advantages of whole exome sequencing is the ability to search the 
complete coding regions of a genome with the potential of revealing a large number of 
rare variants. Currently the sequencing error rate is estimated to be about 1%, which is 
at a similar scale of the frequency of rare variants (Wang et al., 2013). There are 
several issues that can complicate this variant calling step: 1) the presence of indels, a 
major source of false positive in variant identification, 2) variable GC content in short 
reads, an error introduced by library preparation due to PCR artifacts, and 3) variable 
base quality scores (Wang et al., 2013). Filtering was thus critical for achieving high 
quality calls (Kiezun et al., 2012).  
In order to present candidate rare variants with a potential to affect Diabetic 
Retinopathy onset, a rare variant accumulation approach was used. 
Median Number of Variant Calls by Type
300 ± 256
MNP
2601 ± 909
DEL
1807± 981
 INS
49717± 1551
 SNP
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Risk MARKER_ID (chrom: start-end_gene) PASS_MARKERS BURDEN_CNT PVALUE
1:57207874-57257861_C1orf168 4 5 0,0039
22:26164394-26423535_MYO18B 7 8 0,0062
1:215847545-216246585_USH2A 5 5 0,02
15:51743890-51772229_DMXL2 4 4 0,023
8:71025871-71041146_NCOA2 4 6 0,032
16:2287215-2287632_DNASE1L2 3 4 0,033
11:19247163-19258929_E2F8 5 4 0,035
3:195594795-195597000_TNK2 3 3 0,037
14:20711005-20711005_OR11H4 1 2 0,038
19:14029627-14031728_CC2D1A 3 3 0,039
5:37020562-37049406_NIPBL 2 2 0,04
1:9098071-9101726_SLC2A5 2 2 0,042
8:130761778-130774958_GSDMC 2 4 0,043
22:30856091-30857645_SEC14L3 2 2 0,046
6:158910743-158923120_TULP4 3 3 0,048
3.5.1 Candidate Rare Risk Genes  
All rare variants selected and subjected to further gene-wise burden tests 
passed the Hardy-Weinberg equilibrium (HWE ≥ 0.001), with a call rate higher than 
80% and of medium or high severity among other features (presented in Materials and 
Methods, Statistical Analysis). The Gene-wise burden test approach led to 
identification of several genes with an accumulation of rare variants. This list was 
filtered for rare variant accumulating genes with P-value<0.05 and further filtered for 
rare variants present in T2D individuals diagnosed with DR. Thus our rare variant 
search was solely done on the “risk” genes (Tables 5 and 6). 
Table 5. Genes accumulating rare variants in individuals with Diabetic Retinopathy. This list was obtained by a 
Binary Test (cases vs controls). PASS_MARKERS are the number of variants encountered in that gene, BURDEN_CNT 
refers to the number of individuals in which these variants were found. P-values are also represented. 
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Table 6. Genes accumulating rare variants in individuals with Diabetic Retinopathy. This list was 
obtained by a Quantitative Test (cases adjusted to ETDR vs. controls). NUM_PASS_VARS are the 
number of variants encountered in that gene, NUM_SING_VARS refers to the number of variants 
present in only one individual (with DR). P-values are also represented. 
 
Risk MARKER_ID (chrom: start-end_gene) NUM_PASS_VARS NUM_SING_VARS PVALUE
17:72365698-72368711_GPR142 2 1 0,00023708
11:64519437-64527310_PYGM 4 3 0,0010121
1:247614602-247615148_OR2B11 3 2 0,0025469
17:63149547-63189687_RGS9 3 3 0,0026079
1:153587865-153587865_S100A14 1 0 0,002845
17:3101591-3101617_OR1A2 2 2 0,002845
4:140640704-140640704_MAML3 1 0 0,002845
5:178555044-178771135_ADAMTS2 2 2 0,002845
22:26164394-26423535_MYO18B 7 6 0,0029763
16:2287215-2287632_DNASE1L2 3 2 0,0052564
2:130931095-130931167_SMPD4 1 0 0,0056899
3:36756863-36780081_DCLK3 2 2 0,0056899
16:14956982-14989425_NOMO1 3 2 0,0063792
13:25254891-25284616_ATP12A 6 5 0,0081569
19:34180082-34262952_CHST8 3 3 0,0097202
10:125506302-125558631_CPXM2 2 2 0,01138
1:247695273-247695756_OR2C3 3 3 0,01138
19:44681046-44681717_ZNF226 3 3 0,01138
22:45128123-45255629_ARHGAP8 2 2 0,01138
22:45128123-45255629_PRR5-ARHGAP8 2 2 0,01138
5:1254510-1254510_TERT 1 0 0,01138
9:27524515-27524731_IFNK 2 2 0,01138
8:130761778-130774958_GSDMC 2 1 0,011678
15:63920891-64041689_HERC1 3 3 0,012565
11:62984850-62997031_SLC22A25 2 1 0,015884
1:47726135-47746113_STIL 3 3 0,015884
20:43723614-43723669_KCNS1 2 2 0,01707
21:45175604-45175847_PDXK 2 2 0,01707
4:983556-983684_SLC26A1 2 2 0,01707
9:75355093-75355093_TMC1 1 0 0,01707
1:10713845-10720270_CASZ1 3 3 0,019678
4:152499205-152570675_FAM160A1 3 3 0,019678
1:215847545-216246585_USH2A 5 5 0,021222
16:772780-775236_CCDC78 2 2 0,025605
17:43481395-43506940_ARHGAP27 2 2 0,025605
22:41537234-41574925_EP300 2 2 0,025605
5:153432606-153433026_MFAP3 2 2 0,025605
9:107554255-107599376_ABCA1 3 3 0,025605
9:128678097-128678097_PBX3 1 0 0,025605
3:124826801-124906167_SLC12A8 4 3 0,027513
11:65144075-65147013_SLC25A45 1 0 0,029161
11:75298327-75298558_MAP6 3 3 0,029161
6:29407955-29408721_OR10C1 5 1 0,030427
10:103899871-103899970_PPRC1 2 2 0,034139
1:171173089-171178090_FMO2 3 3 0,034139
22:21799719-21800202_HIC2 2 2 0,034139
5:140579961-140581006_PCDHB11 2 2 0,034139
6:36104494-36106712_MAPK13 1 0 0,034139
9:35740293-35740293_GBA2 1 0 0,034139
1:246078824-246078824_SMYD3 1 0 0,034851
3:78676694-78763613_ROBO1 3 3 0,034851
1:94467548-94520733_ABCA4 4 4 0,035006
10:89264706-89265292_MINPP1 2 2 0,045519
11:63276396-63276432_LGALS12 2 2 0,045519
12:110418705-110418705_TCHP 1 0 0,045519
12:111748192-111785678_CUX2 2 2 0,045519
1:223177972-223178706_DISP1 2 2 0,045519
12:57648716-57663716_R3HDM2 2 2 0,045519
16:3100094-3108573_MMP25 2 2 0,045519
16:89293934-89294865_ZNF778 2 2 0,045519
17:77758597-77758597_CBX2 1 0 0,045519
19:2217094-2217786_DOT1L 2 2 0,045519
20:57036604-57042655_APCDD1L 2 2 0,045519
22:30188418-30221173_ASCC2 2 2 0,045519
3:50331133-50332327_HYAL3 2 2 0,045519
19:38893807-38899459_FAM98C 3 2 0,0456
12:56075599-56077768_METTL7B 4 4 0,048364
16:10971206-11002927_CIITA 3 3 0,048364
17:7910817-7915471_GUCY2D 3 2 0,048364
2:238483751-238483751_RAB17 1 0 0,048364
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All rare variant accumulating genes identified (p-value<0.05) were further 
evaluated and their function studied by database and literature search. As there were 
85 genes that fulfilled our filter criteria and being, in the present study, difficult to 
correlate rare variants to the complication, our option was to select those with 
biological relevance and association to mechanisms and pathways related to Diabetic 
Retinopathy pathogenesis. 
From this search, 10 candidate genes aggregated rare risk variants. Three were 
obtained from the binary test approach (cases vs controls) and seven from the 
quantitative test approach (cases adjusted to ETDR vs controls) and were considered 
potentially interesting for a more detailed analysis. 
 
Genes obtained by the binary test (cases vs controls) 
Table 7 presents the results obtained from a published literature review for genes 
Dmx-Like 2 (DMXL2), also known as Rabconnectin3 (Rbcn-3), E2F Transcription Factor 8 
(E2F8) and Deoxyribonuclease I-Like 2 (DNASE1L2). The table details the biological 
function and possible relevance to the DR pathology.  
 
Table 7. Biological function and possible relevance to DR pathology of genes obtained by the 
binary test approach. The associated pathway or mechanism and number of rare variants 
accumulated in the gene are also presented. P-values were obtained by the EPACTS statistical test. 
Gene Biological Function and Relevance 
Associated Pathway or 
Mechanism 
P-
Value 
EPACTS 
Number of 
rare variants 
accumulated 
DMXL2 
Participates in the regulation of the Notch 
signaling pathway (Sethi et al., 2010) 
Notch Signaling 0,023 5 
E2F8 
Promoter of sprouting angiogenesis 
possibly by acting as a transcription 
activator; associates with HIF1A, 
recognizes and binds to the VEGFA 
promoter and activates expression of the 
VEGFα gene (Weijts et al., 2012) 
Angiogenesis 0,035 3 
DNASE1L2 
Expression is induced by TNFα and IL1β via 
the NFKB pathway. Possible physiological 
function under inflammatory conditions. 
(Shiokawa et al., 2004) 
Inflammatory Processes 0,003 3 
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Genes obtained by the quantitative test (cases adjusted to ETDR levels vs 
controls) 
Table 8 presents the results obtained from a published literature review for 
genes MasterMind Like3 (MAML3), ADAM Metallopeptidase with Thrombospondin 
Type1 Motif2 (ADAMTS2), E1A Binding Protein P300 (EP300), Castor Zinc Finger1 
(CASZ1), Adenomatosis Polyposis Coli Down-Regulated 1-Like (APCDD1L), S100 Calcium 
Binding ProteinA14 (S100A14) and G Protein-Coupled Receptor 142 (GPR142). The 
table details the biological function and possible relevance to the DR pathology.  
Table 8. Biological function and possible relevance to DR pathology of genes obtained by the 
quantitative test approach. The associated pathway or mechanism and number of rare variants 
accumulated in the gene are also presented. P-values were obtained by the EPACTS statistical test. 
Gene Biological Function and Relevance  
Associated Pathway 
or Mechanism 
P-Value 
EPACTS 
Number 
of rare 
variants 
MAML3 
Acts as a transcriptional coactivator of NOTCH 
proteins. May be important in the Notch 
signaling pathway (Lin et al., 2002) 
Notch Signaling 0,0028 1 
ADAMTS2 
A metalloproteinase that plays a key role in 
the processing of fibrillar procollagen 
precursors. Is able to reduce the proliferation 
of endothelial cells (Motte et al., 2010). 
Angiogenesis 
0,028 2 
EP300 
Important in cell proliferation and 
differentiation. Has been identified as a co-
activator of HIF1A and plays a role in the 
stimulation of hypoxia-induced genes such as 
VEGFA (Freedman et al., 2002) 
0,025 2 
CASZ1 
Promotes vascular assembly and 
morphogenesis through the direct regulation 
of an EGFL7/RhoA-mediated pathway. SNPs in 
this gene are associated with blood pressure 
variation (Charpentier et al., 2013) 
Vascular Assembly 
and Morphogenesis 
0,019 3 
APCDD1L 
Encodes an inhibitor of the Wnt signaling 
pathway which mediates pathological 
vascular growth in proliferative retinopathy 
(Zhao et al., 2013) 
0,045 2 
S100A14 
Binds to AGE receptors and stimulates RAGE-
dependent signalling cascades, promoting cell 
proliferation. Regulates cell migration by 
modulating levels of MMP2, a matrix protease 
that is under transcriptional control of 
P53/TP53 (Jin et al., 2011) 
0,0028 1 
GPR142 
Rhodopsin-like receptors are a family of 
proteins that comprise the largest group of G-
protein coupled receptors that includes light 
receptors. They transduce extracellular signals 
(Fredriksson et al., 2003) 
G-Protein Coupled 
Receptors 
0,0002 3 
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All variants (from binary test approach and quantitative test approach) were 
confirmed in the BAM files to assure that there were no false positives. The rs ID, 
chromosomal position, impact, impact severity, polyphen prediction, scaled CADD 
value, transcript ID, transcript name and length for the variants are presented in 
Figures E-G (in the Appendix). These tables also refer the individuals that present the 
variant, the respective ETDR values and disease duration (years).  
 
The binary test generated a list of rare variant accumulating genes that may be 
associated to diabetic retinopathy, as can be seen in Figure 28 (A). Rare variants in 
these genes were found in individuals with ETDR levels ranging from 25 to 90. On the 
other hand, the quantitative test generated a list of rare variant accumulating genes 
that are mostly associated to severe diabetic retinopathy, as can be seen in Figure 28 
(B). Rare variants in these genes were found in individuals with ETDR values ranging 
from 43 to 90. 
 
Figure 28. Representation of the rare variant accumulating genes, in T2D individuals with DR, by the 
binary test approach (A) and the quantitative test approach (B). 
Orange cells refer to variants with a scaled CADD value above 14. 
 
The binary test approach (cases vs controls) prioritized rare variant accumulating 
genes that are associated to mild and moderate diabetic retinopathy whereas the 
quantitative test approach (cases adjusted to ETDR values vs controls) prioritized rare 
variant accumulating genes associated to more severe signs of the complication.  
 
Sample EX42 EX12 EX24 EX46 EX17 EX43 EX48 EX49 EX7 EX10 EX23
ETDR level 25 35 35 35 43 47 53 53 90 90 90
Approximate 
Diabetes 
Duration                 
(years)
17 6 22 13 17 5 9 27 33 21 16
E2F8 DNASE1L2 DMXL2 E2F8 DNASE1L2 E2F8 E2F8 DNASE1L2
DMXL2 DNASE1L2 E2F8
DMXL2
CASZ1 APCDD1L EP300 CASZ1 GPR142 GPR142 GPR142
APCDD1L EP300 MAML3 MAML3
CASZ1 S100A14 S100A14
ADAMTS2 ADAMTS2
variants with CADD scaled >14
Variants obtained 
from quantitative 
test
Variants obtained 
from binary test
A 
B 
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Of all rare variant accumulating genes, 2 genes were considered potential 
candidate genes (Table 9). E2F8 and DMXL2 were the genes that presented a larger 
number of variant accumulation, some of which with a deleterious effect according to 
prediction software, and seemed to have, from the published literature research, a 
possible pathophysiological association to Diabetic Retinopathy and were thus further 
explored and validated. The deleteriousness of the candidate variants was assessed 
using Combined Annotation-Dependent Depletion (CADD) scores (Shyr et al., 2014) 
Table 9. Candidate Genes for Diabetic Retinopathy. Genes were selected by the identification of 
rare variants (European Minor Allele Frequency, EUR MAF<0.01) in the group of diabetic retinopathy 
patients. For gene E2F8 5 variants were identified in 21% of retinopathies (p=0.035). For Rbcn-3 
gene 3 variants were found in 13% of case samples (p=0.023). The associated biological mechanisms 
and the type of variant and respective CADD (Combined Annotation Dependent Depletion) are 
described. 
Gene 
Number of rare 
variants 
(MAF < 0.01) 
Individuals 
(%) 
P-value 
(EPACTS) 
Associated 
Mechanisms 
Type of variant 
(predicted impact) 
E2F8 5 21 0.035 
Angiogenesis 
promotion by 
activating the 
transcription of 
VEGFA 
Splice (n.a)  
(CADD 16,62) 
Missense (benign)  
(CADD 3,98) 
Missense (benign)  
(CADD 8,91) 
Missense 
(deleterious)  
(CADD 13,21) 
Missense 
(deleterious)  
(CADD 35) 
DMXL2 3 13 0.023 
Functional regulation 
of the Notch signaling 
pathway 
Missense (benign) 
(CADD 14,65) 
Missense 
(deleterious) 
(CADD 18,03) 
Missense 
(deleterious) 
(CADD 17,19) 
 
The exome sequencing technology was validated by genotyping 8 of the 40 
individuals by Illumina Microarray under the DoIt project. This service was 
subcontracted to ATLAS Biolabs GmbH (Berlin, Germany). For this validation, various 
genotypes obtained, for specific variants, by Ion Torrent Technology, were compared 
with the genotypes obtained by Illumina microarray. More than 98% of the common 
variants (assessed by the Ion Torrent sequencing and the Illumina microarray 
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genotyping) were equal. This procedure validated the next-generation technology used 
in this study.  
 
DMXL2 gene accumulated 3 rare variants in heterozygosity. One of the variants (rs 
114516513) was validated in Ex 49, by the Illumina genotyping microarray. The other 
two variants (positions 51743890 and 51772229 in chromosome 15), present in Ex42 
and Ex24 respectively, which had not rs IDs could not be validated by the same 
procedure and were validated by ASO-PCR. 
E2F8 gene accumulated 5 rare variants in heterozygosity. Three of the variants 
(rs141999878, rs77599073 and rs793274) were validated in Ex 42, Ex49 and Ex46 
respectively, by the Illumina genotyping microarray. The other two variants (positions 
19247162 and 19258928 in chromosome 11), present in Ex7 and Ex49 respectively, 
were validated by ASO-PCR. 
 
We performed ASO-PCR, for all 8 rare variants, in a heterozygote individual, a wild 
type individual and in 20 non T2D individuals. Furthermore, this variant was also 
evaluated in 20 samples which exomes had been previously sequenced at Genoinseq 
in order to check the frequency of this variant in the Portuguese population (Figure 
29). The genotype results for all 40 T2D individuals were also considered in the allele 
frequency determination. 
 
 
Figure 29. Candidate rare variant accumulating genes and validation procedures. 
The validation methods, variants and results are presented. The samples used for heterozygote and wild 
type control are also reported. The allele frequency for the rare variants (1 in 80) was 0.0125. 
 
The various validation procedures confirmed the exome sequencing results. 
 
T/C C/G C/G C/A C/G T/C
rs114516513 Chr15: 51743890 Chr15: 51772229 rs141999878 rs77599073 rs793274
Validation Method Illumina Array Illumina Array Illumina Array Illumina Array
BAM file check      
Variant Confirmation    
Validation Method
Heterozygote Ex49 Ex42 Ex24 Ex42 Ex49 Ex46
Wild Type Ex42 Ex49 Ex49 Ex24 Ex24 Ex24
Allele frequency (24 cases+ 16 
controls + 20 previously 
sequenced exomes  + 20 non 
diabetic individuals) 0.0125 0.0125 0.0125 0.0125 0.0125 0.0125
DMXL2 E2F8
ASO-PCR
Candidate Rare Genes
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DMXL2 (Rbcn-3) gene relation to Diabetic Retinopathy 
 
Confirmation of the variants by BAM file verification is presented in Figure 30. In all 
images the comparison between the heterozygote individual (above) and wild type 
individual (below) is represented. 
 
Figure 30. BAM file verification of the 3 rare variants in DMXL2 gene. 
A. rs114516513: HT – Ex49 and WT – Ex24. B. 15:51743889: HT – Ex42 and WT – Ex49. C. 15:51772228: HT – 
Ex24 and WT – Ex49. 
 
An example of the ASO-PCR genotyping for the 3 rare variants in gene DMXL2 is 
represented in Figure 31. The electrophoresis gel refers to the T2D individual with DR 
that had the variant and was thus considered our heterozygote, a T2D individual with 
DR that did not present the variant and was thus our wild type control and 4 non T2D 
individuals. The 16 other non T2D individual genotypes are presented in the Appendix. 
 
Figure 31. Examples of the electrophoresis gel results from the ASO-PCR genotyping validation of the 3 
variants in DMXL2 gene. 
The red arrows depict the genotype of the T2D individual with the rare variant and thus our heterozygote 
control. The blue arrows depict a T2D individual that did not have the variant and thus our wild type 
homozygous control. The result for 4 control individuals are also represented. All individuals for all variants 
were wild type. Every two wells correspond to an individual/genotype. A. rs114516513 T/C; B. 15:51743889 
C/G; C. 15:51772228 C/G. 
 
A 
B 
C 
A B C 
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The first phases of Diabetic Retinopathy are characterized by the thickening of the 
basal membrane, loss of inter-endothelial tight junctions and early and selective loss of 
pericytes accompanied by an increase in the vascular permeability, capillary 
occlusions, microaneurisms and loss of endothelial cells. Pericytes are responsible for 
vascular stability and control endothelial proliferation and the loss of these contractile 
cells is a hallmark of Diabetic Retinopathy (Arboleda-Velasquez et al., 2014). 
 
It has been demonstrated that the Notch signaling pathway has an important role 
in the survival of the pericytes. For an efficient signaling, Notch membrane receptors 
need to be cleaved and its intracellular domains, Notch IntraCellular Domains (NICD), 
internalized to the nucleus where they function as transcription factors for target 
genes. DMXL2, also known as Rabconnectin-3 (Rbcn3) influences the Notch signaling 
by its involvement in the acidification of intracellular compartments by the V-ATPase 
complex. These endocytic compartments modify the activity of γ-secretase, which 
cleaves NICD, and/or affects the liberation of NICD (Sethi et al., 2010, Roca & Adams, 
2007) 
 
Figure 32. Maturation of the notch receptor involves cleavage at the prospective extracellular side during 
intracellular trafficking. 
This results in a bipartite protein, composed of a large extracellular domain linked to the smaller 
transmembrane and intracellular domain. Binding of ligand promotes two proteolytic processing events; as 
a result of proteolysis, the intracellular domain is released and can enter the nucleus to engage other DNA-
binding proteins and regulate gene expression. Adapted from 
http://www.onclive.com/publications/Oncology-live/2013/February-2013/Notch-Signaling-Tackling-a-
Complex-Pathway-With-a-New-Generation-of-Agents 
 59 
 
 
E2F8 gene relation to Diabetic Retinopathy 
 
The confirmation of the variants by BAM file verification is shown in Figure 33. In all 
images the comparison between the heterozygote individual (above) and wild type 
individual (below) is represented. 
 
 
 
 
Figure 33. BAM file verification of the 5 rare variants in E2F8 gene. 
A. rs141999878: HT – Ex42 and WT – Ex24. B. rs77599073: HT – Ex49 and WT – Ex24. C. rs793274: HT – Ex46 
and WT – Ex24. D. 11:19247162: HT – Ex7 and WT – Ex24. E. 11: 19258928: HT –Ex49 and WT –Ex24. 
 
An example of the ASO-PCR genotyping for the 5 rare variants in gene E2F8 is 
represented in Figure 34. The electrophoresis gel refers to the T2D individual with DR 
that had the variant and was thus considered our heterozygote, a T2D individual with 
DR that did not present the variant and was thus our wild type control and 4-6 non T2D 
individuals. The 14-16 other non T2D individual genotypes are presented in the 
Appendix. 
A B C 
D E 
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Figure 34. Examples of the electrophoresis gel results from the ASO-PCR genotyping validation of the 5 
variants in E2F8 gene. 
The red arrows depict the genotype of the T2D individual with the rare variant and thus our heterozygote 
control. The blue arrows depict a T2D individual that did not have the variant and thus our wild type 
control. The result for 4 or 5 control individuals are also represented. All individuals for all variants were 
wild type. Every two wells correspond to an individual/genotype. A. rs141999878 C/A. B. rs77599073 C/G. 
C. rs793274 T/C. D. 11:19247162 C/G. E. 11: 19258928 C/T. 
 
E2F7 and E2F8 are the most recent members of the E2F transcription factor family 
and having been reported as essential in the adequate formation of blood vessels, act 
as promotors of germinative angiogenesis, the extension of new blood vessels by 
proliferation of the endothelial cells of pre-existent capillaries, by activating the 
transcription of the Vascular Endothelial Growth Factor A (VEGFA) gene. 
E2F7/E2F8 forms a transcriptional complex with the Hypoxia Inducible Factor 1 
(HIF1A), recognizes and binds to the VEGFA promoter and activates the expression of 
the VEGFA gene (Weijts et al., 2012). 
 
Figure 35. Schematic representation of the activation of the VEGFA promoter by HIF1A. 
HIF1A consists of two subunits: an inducibly expressed HIF1 alpha subunit and a constitutively-expressed 
HIF1 beta subunit. Under hypoxia, HIF1α becomes stable and interacts with coactivators such as p300 to 
modulate its transcriptional activity. Adapted from Ghosh et al., 2009. It has been proposed that E2F7/F8 
forms a transcriptional complex with HIF1A (Weijts et al., 2012). 
 
 
 
 E2F7+E2F8 
A B 
C D 
E 
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From what we could gather, E2F8 and DMXL2 seem to be involved in the 
mechanisms related to Diabetic Retinopathy. However, further studies have to be 
conducted before considering the association of these genes to the onset, 
development or aggravation of Diabetic Retinopathy.  
In the future, the genotyping of a much larger population and gene functional 
studies should give a better idea of the relevance of these potential genetic markers. 
 
3.6 Candidate Common Variants 
To the list of common variants, after statistical analysis, no other filter was applied 
as to increase the possibility of encountering common variants that could be 
biologically relevant to the pathogenesis of the complication. There was a need to 
define a prioritization procedure as the number of common variants was large.  
 
Genes that had been referred in the literature as possibly associated to the disease 
and had a p-value<0.05 were checked.  
From this approach, 11 common variants (rs1035798 in AGER, rs62357156 in 
ITGA1, rs7125062 in MMP1, rs80067372 in TNFSF12, rs9907595 in PLXDC1, rs2296123 
in PRKCQ and rs7483 in GSTM3, rs4434138 and rs4234633 in STAB1, rs10794640 in 
NARFL and rs4698803 in EGF were found. 
 
The list of 11 variants that were considered biologically relevant and potentially 
related to the pathways that have been documented as participants in the 
development of DR are represented in Table 10.  
Six were considered risk variants (rs1035798, rs62357156, rs7125062, rs80067372, 
rs4434138 and rs4234633) with an Odds Ratio>1 and encountered in T2D patients that 
were diagnosed with DR and five (rs10794640, rs9907595, rs2296123, rs7483 and 
rs4698803), with an Odds Ratio<1 were considered protective variants associated to 
the group of T2D patients without DR. 
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Table 10. Common genetic variants associated with Diabetic Retinopathy. The frequency of the minor allele 
identified in the Diabetic Retinopathy patients group (DR), controls and in the European population (1000 
Genomes Project) is described for each SNP. The genotypic frequencies between patients with and without DR 
were analyzed by multinomial logistic regression, adjusted to the following co-variates: age, sex, disease 
duration and glycated hemoglobin.  
ID rs Gene Ref Alt 
MAF 
(DR) 
MAF 
(controls) 
MAF 
(EUR) 
P-
value 
OR (IC 95%) 
Associated 
Mechanisms 
rs1035798 AGER G A 0.42 0.16 0.23 0.011 
22.298 
(2.027-245.257) 
AGE/AGER signaling 
pathway 
rs62357156 ITGA1 T A 0.33 0.06 0.17 0.008 
23.568 
(2.249-246.990) 
Cell-cell adhesion 
and Endothelial Cell 
migration 
rs7125062 MMP1 T C 0.40 0.09 0.25 0.034 
6.336 
(1.152-34.837) 
VEGFA dependent 
angiogenesis 
rs80067372 TNFSF12 G A 0.44 0.19 0.23 0.038 
5.986 (1.108-
32.344) 
TWEAK/Fn-14 
pathway and 
pathogenic 
neovascularisation 
rs4434138 
STAB1 
A G 0.69 0.33 0.47 0.009 
3.898 (1.405-
10.817) 
Internalization and 
trafficking of 
Advanced Glycated 
End (AGE) products rs4234633 C T 0.67 0.31 0.46 0.012 
3.769 (1.334-
10.649) 
rs10794640 IOP1 G A 0.04 0.28 0.22 0.007 
0.10 (0.000-
0.293) 
Modulation of 
HIF1A 
rs9907595 PLXDC1 G A 0.08 0.34 0.23 0.014 
0.043 (0.003-
0.535) 
Fibrovascular 
membrane 
formation 
rs2296123 PRKCQ C G 0.25 0.59 0.36 0.015 
0.253 (0.084-
0.766) 
Pro-inflammatory 
gene expression 
rs7483 GSTM3 C T 0.21 0.44 0.31 0.033 
0.308 (0.104-
0.908) 
Detoxification of 
Reactive Oxygen 
Species (ROS) 
rs4698803 EGF T A 0.06 0.31 0.20 0.041 
0.137 (0.02-
0.919) 
EGF-VEGF signaling 
pathway 
 
All common variants listed above were checked in the BAM files and validated as 
real.  
Besides this verification, four common variants were confirmed by the Illumina 
Microarray: rs7125062 T/C, rs9907595 G/A, rs7483 C/T and rs4698803 T/A and 
rs1035798 G/A was confirmed by OpenArray Technology (Life Technologies, CA, USA), 
a study previously performed at Genoinseq. 
All other variants were validated by Sanger sequencing of two homozygous and 
two heterozygous individuals (Figure 36). Once again, all variant results were 
confirmed. 
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Figure 36. Candidate common variants and validation procedures. 
The validation methods, variants and results are presented. The homozygote and heterozygote samples 
used for Sanger sequencing are also reported. Risk variants are coloured in red and protective variants are 
coloured green. 
 
3.6.1 Risk Variants 
rs1035798 G/A variant in the AGER gene 
The splice region variant in AGER was confirmed in the respective BAM file (Figure 
37). The information regarding the variant is presented in Table 11.  
 
 
Figure 37. BAM file of sequenced data for rs1035798 G/A variant in AGER gene. 
IonXpress_011 refers to Ex11 which is an altered homozygous (A/A) and IonXpress_007 refers to Ex23 which 
is heterozygous (G/A) for the variant. 
 
Table 11. rs1035798 G7A genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented.  
rs ID Gene Impact Impact severity CADD scaled 
Reference 
Homozygous                  
(%) 
Heterozygous 
(G/A) (%) 
Altered 
Homozygous 
(A/A) (%) 
rs1035798 AGER Splice region Medium 0,01 43% 53% 5% 
 
  
AGER ITGA1 MMP1 TNFSF12 IOP1 PLXDC1 PRKCQ GSTM3 EGF
G/A T/A T/C G/A A/G C/T G/A G/A C/G C/T T/A
rs1035798 rs62357156 rs7125062 rs80067372 rs4434138 rs4234633 rs10794640 rs9907595 rs2296123 rs7843 rs4698803
Validation Method Open Array Illumina Array Illumina Array Illumina Array Illumina Array
BAM file check           
Variant Confirmation     
Validation Method Sanger Sanger Sanger Sanger
Homozygote Ex30 Ex49 and Ex10 Ex19 Ex50 and Ex2
Heterozygote Ex26 and Ex47 Ex47 and Ex9 Ex29 and Ex45 Ex10 and Ex23
Sanger
Candidate Common Variants
STAB1
Risk Variants
Protective Variants
Ex42 and Ex46
Ex37 and Ex41
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AGER gene relation to Diabetic Retinopathy 
 
The receptor for Advanced Glycated End products (AGER), encoded by this gene is 
a member of the cellular immunoglobin receptors. It is a receptor of multiple ligands 
that besides interacting with AGE, also interacts with molecules implicated in 
homeostasis and inflammation in certain diseases such as Diabetes and Alzheimer. 
AGE are non- enzymatic glycosilated proteins that accumulate in vascular tissues and 
promote inflammation. It has been documented that chronic inflammation alters the 
micro and macro vasculature leading to damaged organs (van den Oever et al., 2010). 
The AGE/AGER signaling pathway has an important role in the regulation and 
expression of TNF-α, oxidative stress and endothelial dysfunction in Type 2 Diabetes. 
(Falcão et al., 2010) 
 
 
rs62357156 T/A variant in the ITGA1 gene 
 
The intron variant in ITGA1 was confirmed in the respective BAM file (Figure 38). 
The information regarding the variant is presented in Table 12.  
 
 
Figure 38. BAM file of sequenced data for rs62357156 T/A variant in ITGA1 gene. 
IonXpress_014 refers to Ex30 which is an altered homozygous (A/A) and IonXpress_015 refers to Ex47 which 
is heterozygous (T/A) for the variant. 
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Table 12. rs62357156 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity 
CADD 
scaled 
Reference 
Homozygous                  
(%) 
Heterozygous 
(T/A) (%) 
Altered 
Homozygous 
(A/A) (%) 
rs62357156 ITGA1 intron LOW 4,75 58% 40% 3% 
 
 
This variant was validated, by Sanger sequencing, of Ex30, a homozygote (A/A) and 
Ex26 and Ex47, 2 heterozygotes (T/A) (Figure 39). 
 
 
Figure 39. Chromatograms of the sequenced ITGA1 partial gene validating the findings of rs62357156 
(T/A) variant. 
A. Ex30 (A/A). B. Ex26 (T/A). C. Ex47 (T/A) 
 
 
ITGA1 gene relation to Diabetic Retinopathy 
 
The ITGA1 gene encodes the α subunit of the integrin receptors. The integrin 
receptor heterodimerizes with the β subunit to form a cell-surface receptor for 
collagen and laminin (Figure 40).  
It is involved in cell-cell adhesion and may affect the mobility and proliferation of 
endothelial cells or inhibit their activities. The dysfunction of endothelial cells may 
promote the development of chronic inflammatory conditions and lead to vascular 
diseases. ITGA1, mediates physiological angiogenesis and is involved in the regulation 
of angiogenesis in pathological conditions, hence the possible relation to Diabetic 
Retinopathy (Park et al., 2014) 
 
  
C B A 
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Figure 40. Integrin conformation-function 
relationships: a model. 
A five-component model illustrating conformational 
changes that are associated with inside-out and 
outside-in integrin signalling. The α-subunit is in red 
and the β-subunit in blue. The figure shows the three 
major conformational states that have been 
identified so far: inactive (A), primed (B) and ligand 
bound (C) (ligand is represented by a green triangle), 
together with possible intermediate conformers. 
Panels A-C represent conformations that mediate 
inside-out signalling, and panels D and E, outside-in 
signalling (the direction is indicated by red arrows). 
Adapted from Askari et al., 2009. 
 
 
 
 
rs7125062 T/C variant in the MMP1 gene 
 
The intron variant in MMP1 gene was confirmed in the respective BAM file (Figure 
41). The information regarding the variant is presented in Table 13.  
 
 
Figure 41. BAM file of sequenced data for rs7125062 T/A variant in MMP1 gene. 
IonXpress_011 refers to Ex11 which is an altered homozygous (C/C) and IonXpress_002 refers to Ex34 which 
is heterozygous (T/C) for the variant. 
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Table 13. rs7125062 T/C genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity 
CADD 
scaled 
Reference 
Homozygous                  
(%) 
Heterozygous 
(T/C)                       
(%) 
Altered 
Homozygous 
(C/C)                       
(%) 
rs7125062 MMP1 intron LOW 6,77 55% 35% 10% 
 
 
MMP1 gene relation to Diabetic Retinopathy 
 
The angiogenic switch from normal to abnormal sprouting of new blood vessels from 
preexisting ones involves, in part, the proteolytic degradation of basement membranes 
and extracellular cell (ECM) components by Matrix Metalloproteinases (MMPs) (El-
Asrar et al., 2013).  
MMPs are a family of zinc ion-binding Ca
2+
-dependent neutral endopeptidases that 
act together with other enzymes to degrade most components of the ECM. Under 
steady state physiologic conditions, the expression of MMPs in most tissues is 
relatively low but recent studies have indicated that certain MMPs are generally up-
regulated in several conditions that accompany angiogenesis and play an important 
role in the initiation of this process.  
 
MM1 and MMP9 levels are increased dramatically in Proliferative Diabetic 
Retinopathy (PDR) and may be linked to the progression of the complication (El-Asrar 
et al., 2013). MMP-1, an interstitial collagenase, acts directly on human microvessel 
endothelial cells as a pro-angiogenic signaling molecule and induces the expression of 
different subsets of pro-angiogenic genes (El-Asrar et al., 2013). In addition to 
removing the physical barriers to new vessel growth, MMPs proteolytically release 
VEGF from the ECM-associated reservoirs, resulting in increased VEGF bioavailability 
and triggering the VEGF-driven angiogenic switch (El-Asrar et al., 2013) (Figure 42). 
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Figure 42. A. The response to an angiogenic stimulus. 
1) pericyte attachment and endothelial cell contacts are disrupted 
and the basement membrane is degraded by MMPs, 2) cell-matrix 
mediates the outgrowth of an endothelial tip cell followed by stalk 
cell proliferation, 3) endothelial cell migrates and proliferates in 
response to VEGF, FGFs and MMPs; 4) endothelial cell aligns and 
forms new chords leading to 5) vessel maturation. Factors which 
control the various steps are listed. Adapted from Chung & Ferrara, 
2010. B. Specific MMPs and their cellular sources in an 
atherosclerotic blood vessel. Endothelial cells express a number of 
MMPs, including MMP-1, -2, -9, -13, and -14. Adapted from Austin 
et al., 2013. 
 
 
 
rs80067372 G/A variant in theTNFSF12 gene 
 
The intron variant in TNFSF12 gene was confirmed in the respective BAM file 
(Figure 43). The information regarding the variant is presented in Table 14.  
 
 
Figure 43. BAM file of sequenced data for rs80067372 G/A variant in TNFSF12 gene. 
IonXpress_008 refers to Ex24 which is an altered homozygous (A/A) and IonXpress_001 refers to Ex33 which 
is heterozygous (G/A) for the variant. 
 
 
B 
A 
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Table 14. rs80067372 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity CADD scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(G/A) (%) 
Altered 
Homozygous 
(A/A) (%) 
rs80067372 TNFSF12 intron LOW 8,21 40% 53% 8% 
 
This variant was validated, by Sanger sequencing, of Ex49 and Ex10, 2 homozygotes 
(A/A) and Ex47 and Ex9, 2 heterozygotes (G/A) (Figure 44). 
 
Figure 44. Chromatograms of the sequenced TNFSF12 partial gene validating the findings of 
rs80067372(G/A) variant. 
A. Ex49 (A/A). B. Ex10 (A/A). C. Ex47 (G/A) and D. Ex9 (G/A). 
 
TNFSF12 gene relation to Diabetic Retinopathy 
 
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis 
factor (TNF) ligand family. TNFSF12, (TWEAK) is a ligand for the receptor 
FN14/TWEAKR (Figure 45). Existing in the membrane form it is secreted and found to 
promote proliferation and migration of endothelial cells, and thus acts as a regulator of 
angiogenesis.  
The TWEAK/Fn-14 (TNF-like weak inducer of apoptosis/ fibroblast growth factor 
inducible-14) pathway is involved in the pathological neovascularization in the retina, 
associated to Proliferative Diabetic Retinopathy. It seems that Hypoxia inducible 
factor-1α (HIF1A) is likely implicated in the upregulation of Fn14. (Ameri et al., 2014)  
A B C D 
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Figure 45. Pathological actions of TWEAK/Fn14 interaction. 
Fn14 is almost absent in healthy tissues. After injury, Fn14 is upregulated, facilitating the interaction with its 
ligand TWEAK and its trimerization. In a context of chronic injury, TWEAK/Fn14 interaction participates in 
pathological tissue remodeling, promoting proliferation, migration, differentiation, apoptosis, inflammation, 
angiogenesis, and matrix degradation. Adapted from Ameri et al, 2014. 
 
 
rs4434138 A/G and rs4234633 (C/T) variant in STAB1 gene 
 
The non-synonymous coding and splice region variants in STAB1 gene were 
confirmed in the respective BAM file (Figure 46). The information regarding the variant 
is presented in Table 15.  
 
 
Figure 46. BAM file of sequenced data for rs4434138 A/G variant (A) and rs4234633 C/T (B) in STAB1 
gene. 
IonXpress_011 refers to Ex43 which is an altered homozygous (G/G) and (T/T) and IonXpress_005 refers to 
Ex37 which is heterozygous (A/G) and (C/T) for the variants, correspondingly. 
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Table 15. rs4434138 and rs4234633 genotype frequencies in our study population (40 individuals). 
The type of variant, its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity CADD scaled 
Reference 
Homozygous                  
(%) 
Heterozygous          
(%) 
Altered 
Homozygous                       
(%) 
rs4434138 
STAB1 
non_syn_coding MED 11,31 25% 28% 48% 
rs4234633 splice_region MED 8,91 25% 25% 50% 
 
These variants were validated, by Sanger sequencing, of Ex42 and Ex46, 2 
homozygotes (G/G) for rs4434138 and (T/T) and (C/T) for rs4234633, respectively and 
Ex37 and Ex41, 2 heterozygotes (A/G) for rs4434138 and (C/T) for rs4234633. These 
variants seem to be in linkage in all the samples sequenced except for Ex46 which is 
homozygous for one variant and heterozygous for the other (Figure 47).  
 
 
Figure 47. Chromatograms of the sequenced STAB1 partial gene validating the findings of rs4434138 
(A/G) and rs4234633 (C/T) variants. 
A and B. Ex42 (G/G) and (T/T). C. and D. Ex46 (G/G) and (C/T). E. and F. Ex37 (A/G) and (C/T) and G. and H. 
Ex41 (A/G) and (C/T). 
 
STAB1 has been classified as a FrequentLy mutAted GeneS (FLAGS) but was 
considered relevant for further study. The two variants revealed having a Medium 
severity and appeared in the list of candidate common variants because it was present 
in one of the groups (cases). 
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STAB1 gene relation to Diabetic Retinopathy 
 
Stabilin1 (STAB1), also known as Fasciclin EGF-like, laminin-type EGF-like, and 
Link domain-containing scavenger receptor-1 (FEEL1) is a type-1 transmembrane 
receptor that mediates endocytis and phagocytic clearance of "unwanted-self" 
components (Figure 48). It is expressed by the liver and vascular tissues, recognizes 
Advanced Glycation End products (AGEs) and may have a significant role in its' 
elimination from circulation as well as in the development of diabetic vascular 
complications (Tamura et al., 2003; Kzhyshkowska et al., 2006; Kzhyshkowska et al., 
2010). 
The matrix cellular glycoprotein SPARC (secreted protein acidic and rich in cysteine) is 
a soluble, non-structural component of extracellular matrix (ECM) implicated in 
developmental processes, tissue remodeling, angiogenesis, and wound healing. It 
exhibits its multiple biological functions by active modulation of ECM organization, 
binding to growth factors, and induction of an anti-adhesive state in different cell 
types (Kzhyshkowska et al., 2006). It modulates angiogenesis by multiple mechanisms 
including the promotion of endothelial cell deadhesion, modulation of vascular ECM, 
and enhancement of the permeability of endothelial monolayers.  
Both SPARC and stabilin-1 are expressed in normal adult tissues and under 
pathological conditions characterized by exuberant ECM production and/or cellular 
turnover. 
Stabilin-1 is expressed by cells specialized in the clearance of “unwanted self” and in 
the maintenance of tissue homeostasis and it has been demonstrated that it 
internalizes and targets SPARC to an endosomal pathway for lysossomal degradation 
(Kzhyshkowska et al., 2006). 
 
 
Figure 48. Schematic representation of stabilin-1 
trafficking pathways. 
Upon binding to surface expressed stabilin-1, ligand is 
internalized and delivered to early/sorting endosomes 
(EE). A portion of the ligand-free receptor can recycle 
back to the cell surface via recycling endosomes (RE). 
Stabilin-1 delivers its ligand to late endosomes (LE). 
Endocytic ligands (green) are further degraded in 
lysosomes. Adapted from Kzhyshkowska et al., 2006. 
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3.4.1 Protective Variants 
rs10794640 G/A variant in the NARFL gene (IOP1) 
 
The non-synonymous coding variant in NARFL gene was confirmed in the 
respective BAM file (Figure 49). The information regarding the variant is presented in 
Table 16.  
 
 
Figure 49. BAM file of sequenced data for rs10794640 G/A variant in IOP1 gene. 
IonXpress_003 refers to Ex19 which is an altered homozygous (A/A) and IonXpress_013 refers to Ex29 which 
is heterozygous (G/A) for the variant. 
 
Table 16. rs10794640 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity CADD scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(G/A) (%) 
Altered 
Homozygous 
(A/A) (%) 
rs10794640 NARFL non_syn_coding MED 1,06 75% 23% 3% 
 
 
This variant was validated, by Sanger sequencing, of Ex19, a homozygote (A/A) and 
Ex29 and Ex45, 2 heterozygotes (G/A) for the variant (Figure 50). 
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Figure 50. Chromatograms of the sequenced NARFL partial gene validating the findings of rs10794640 
(G/A) variant. 
A. Ex19 (A/A). B. Ex29 (G/A) and C. Ex45 (G/A). This gene is in reverse strand (-1). 
 
 
NARFL gene relation to Diabetic Retinopathy. 
 
NARFL (Nuclear Prelamin A Recognition Factor-Like) is a protein coding gene also 
known as IOP1 (iron-only hydrogenase-like 1). Evidence has shown that IOP1 is a 
component of the protein network that regulates HIF-1α in cells. (Huang et al., 2007). 
 
Transcription factor HIF-1 (hypoxia-inducible factor-1) plays an important role in 
cellular response to systemic oxygen levels and a central means by which cells respond 
to low oxygen tension is through the activation of this transcription factor. It is a 
heterodimeric complex consisting of α and β subunits, being the α subunits, the 
primary oxygen-responsive components of the HIF complex.  
Under normoxic conditions, HIF-1α is targeted for rapid degradation by the 
ubiquitin–proteasome pathway. Under hypoxic conditions, this degradation is 
inhibited, thereby leading to the stabilization and activation of HIF-1α (Figure 51). HIF-
1 α heterodimerizes with the β subunit and forms a complex that binds to promoters 
and enhancers of a multitude of genes involved in cellular, local and systemic 
responses to hypoxia. These include genes encoding proteins involved in angiogenesis, 
such as vascular endothelial growth factor (VEGF) (Huang et al., 2007). Studies have 
demonstrated that NARFL (IOP1) knockdown up-regulates HIF-1α protein levels and 
augments hypoxia-induced target gene expression. It seems NARFL maintains HIF-1α 
mRNA levels at low steady-state levels. 
 
A B C 
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Figure 51. In normoxia, the cellular oxygen sensors (PHDs) hydroxylate HIF-1α, leading to its proteosomal 
degradation mediated by pVHL, an E3 ubiquitin ligase. 
During hypoxia, HIF-1α is not ubiquitinylated or degraded, and acts as a transcription factor that binds to 
Hypoxia Responsive Elements (HREs) to induce expression of a plethora of target genes, including VEGF, 
which promotes angiogenesis. Abbreviations: HIF, hypoxia-inducible transcription factor; HRE, hypoxia 
response element; PHD, prolyl hydroxylase; pVHL, von Hippel–Lindau protein; VEGF, vascular endothelial 
growth factor; VEGFR, VEGF receptor. Adapted from Maes et al., 2012. 
 
 
rs9907595 A/G variant in PLXDC1 gene  
 
The intron variant in PXLDC1 gene was confirmed in the respective BAM file (Figure 
52). The information regarding the variant is presented in Table 17.  
 
 
Figure 52. BAM file of sequenced data for rs9907595 A/G variant in PLXDC1 gene. 
IonXpress_012 refers to Ex28 which is a homozygous (A/A), IonXpress_002 refers to Ex18 which is 
heterozygous (A/G) and IonXpress_010 refers to Ex26 which is homozygous (G/G) for the variant. In this 
case, the A is the minor allele. 
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Table 17. rs9907595 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled cadd value is also represented. The A allele is the minor allele. 
rs ID Gene Impact Impact severity 
CADD 
scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(A/G) (%) 
Altered 
Homozygous 
(G/G) (%) 
rs9907595 PLXDC1 intron LOW 13,94 3% 33% 65% 
 
 
PLXDC1 gene relation to Diabetic Retinopathy 
 
Much of the retinal damage that characterizes advanced Proliferative Diabetic 
Retinopathy results from retinal neovascularization (Yamaji et al., 2008; El-Asrar et al., 
2013). When the newly formed vessels are associated with fibrous proliferations 
forming fibrovascular membranes (FVMs), traction retinal detachments can develop, 
resulting in potentially severe vision loss. Human retinal neovascularization exploits 
the same genes used by the developing normal endothelial cells and is regulated by a 
balance between stimulators and inhibitors of angiogenesis, thought to tightly control 
the normally quiescent capillary vasculature. When this balance is upset, as in PDR, 
capillary endothelial cells proliferate. (Yamaji et al., 2008).  
Plexin domain-containing 1 (PLXDC1), also known as TEM7 (Tumor Endothelial 
Marker 7), may play a significant role in the proliferation and maintenance of 
neovascular endothelial cells in the FVMs. It has been demonstrated (Yamaji et al., 
2008) that the TEM7 expression is specifically enhanced in neovascular endothelial 
cells in the FVMs associated with PDR and its' presence further supports the idea that 
they are markers of neoangiogenesis (Figure 53). 
In addition to the biological interest of the TEM7 gene, the presence of a secreted 
form of TEM7 in FVMs raises a clinically interesting possibility for the development of 
novel serum markers that can be used to predict retinal angiogenic activity, which may 
reflect disease severity in patients with PDR. TEM7 may also be a molecular target for 
new diagnostic and therapeutic strategies for PDR. 
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Figure 53. Severe proliferative diabetic retinopathy with vitreous haemorrhage (large black arrows), a 
huge fibrovascular membrane (small black arrows) that causes traction retinal detachment (white 
arrows). 
Adapted from Gotzaridis et al., 2004. 
 
 
rs2296123 C/G variant in the PRKCQ gene  
 
The intron variant in PRKCQ gene was confirmed in the respective BAM file (Figure 
54). The information regarding the variant is presented in Table 18.  
 
 
 
Figure 54. BAM file of sequenced data for rs2296123 C/G variant in PRKCQ gene. 
IonXpress_002 refers to Ex50 which is an altered homozygous (G/G) and IonXpress_007 refers to Ex7 which 
is heterozygous (C/G) for the variant. 
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Table 18. rs2296123 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled cadd value is also represented. 
rs ID Gene Impact Impact severity 
CADD 
scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(C/G) (%) 
Altered 
Homozygous 
(G/G) (%) 
rs2296123 PRKCQ intron LOW 8,58 40% 45% 15% 
 
 
This variant was validated, by Sanger sequencing, of Ex50 and Ex2, 2 homozygotes 
(G/G) and Ex10 and Ex23, 2 heterozygotes (C/G) for the variant (Figure 55). 
 
 
 
Figure 55. Chromatograms of the sequenced PRKCQ partial gene validating the findings of rs2296123 
(C/G) variant. 
A. Ex50 (G/G). B. Ex2 (G/G). C. Ex10 (C/G) and D. Ex23 (C/G). This gene is in reverse strand (-1). 
 
 
PRKCQ gene relation to Diabetic Retinopathy 
 
Protein Kinase C, ζ is encoded by the PRKQ gene and is one of the members of the 
Protein Kinase C family and reveals being necessary for the activation of T cells. It is a 
kinase protein that is independent of Ca
2+
 and requires Diacylglycerol (DAG) for the 
activation of NF-KB and AP-1. It may have an important role in the binding of the T 
signaling receptors complex with the concomitant activation of transcription factors. 
The increase in NF-KB induces the expression of pro-inflammatory genes. (Heo et al., 
2011) 
  
A B C D 
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rs7483 C/T variant in GSTM3 gene  
 
The non-synonymous coding variant in GSTM3 gene was confirmed in the 
respective BAM file (Figure 56). The information regarding the variant is presented in 
Table 19. 
 
Figure 56. BAM file of sequenced data for rs7843 C/T variant in GSTM3 gene.  
IonXpress_006 refers to Ex38 which is an altered homozygous (T/T) and IonXpress_015 refers to Ex47 which 
is heterozygous (C/T) for the variant. 
 
Table 19. rs7843 genotype frequency in our study population (40 individuals). The type of variant, 
its impact severity and scaled CADD value is also represented. 
rs ID Gene Impact Impact severity 
CADD 
scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(C/T) (%) 
Altered 
Homozygous 
(T/T) (%) 
rs7483 GSTM3 non_syn_coding MED 0,01 53% 35% 13% 
 
GSTM3 gene relation to Diabetic Retinopathy 
 
Oxidative stress is considered as one of the crucial contributors in the pathogenesis 
of diabetic retinopathy, but oxidative stress appears to be highly interrelated with 
other biochemical imbalances that lead to structural and functional changes and 
accelerated loss of capillary cells in the retinal microvasculature and, ultimately, 
pathological evidence of the disease. (Madsen-Bouterse and Kowluru, 2008). This gene 
encodes a glutathione S-transferase that belongs to the mu class which functions in 
the detoxification of electrophilic compounds, including carcinogens, therapeutic 
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drugs, environmental toxins and products of oxidative stress, by conjugation with 
glutathione. 
 
rs4698803 A/T variant in the EGF gene  
 
The non-synonymous coding variant in EGF gene was confirmed in the respective 
BAM file (Figure 57). The information regarding the variant is presented in Table 20. 
 
 
Figure 57. BAM file of sequenced data for rs4698803 A/T variant in EGF gene. 
IonXpress_003 refers to Ex19 which is a homozygous (A/A), IonXpress_005 refers to Ex37 which is 
heterozygous (A/T) and IonXpress_004 refers to Ex4 which is homozygous (T/T) for the variant. In this case, 
the A is the minor allele. 
 
Table 20. rs4698803 genotype frequency in our study population (40 individuals). The type of 
variant, its impact severity and scaled CADD value is also represented. The A is the minor allele.  
 
EGF gene relation to Diabetic Retinopathy 
 
The EGF gene encodes a member of the epidermal growth factor superfamily. This 
protein acts a potent mitogenic factor that plays an important role in the growth, 
proliferation and differentiation of numerous cell types. It binds to a high affinity cell 
surface receptor, the Epidermal Growth Factor Receptor (EGFR) that after activation by 
mechanisms of homo/heterodimerization and autophosporylation, initiate a signaling 
rs ID Gene Impact 
Impact 
severity 
CADD 
scaled 
Reference 
Homozygous 
(%) 
Heterozygous 
(A/T) (%) 
Altered 
Homozygous 
(T/T) (%) 
rs4698803 EGF non_syn_coding MED n.d 8% 18% 75% 
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cascade leading to altered gene expression and augmented cellular proliferation. The 
EGF signaling pathway is thus activated and can interact with other processes, such as 
the VEGF pathway (Figure 58). Being closely related they share common downstream 
signaling pathways. It has been shown that EGF is one of the many growth factors that 
drive VEGF expression (Tabernero, 2007).  
The formation of new vessels begins with hemangioblasts (precursors of vascular 
endothelial cells) and ends with mature vasculature. It is a complex process that is 
regulated tightly by proangiogenic and antiangiogenic factors and involves autocrine 
and paracrine signaling. Thus mediation of VEGF expression is one of the main 
mechanisms by which tissue vasculature is controlled under normal physiologic 
conditions. Overexpression of EGFR and dysregulation or increased activity of EGFR 
signaling pathways are suggested mechanisms whereby the presence of EGFR may 
confer or promote a malignant phenotype. It is postulated that increased EGFR-
mediated signaling may contribute to a cell moving into a state of continuous, 
unregulated cell proliferation.  
Studies have found that treatment with EGF receptor inhibitors reduced retinal 
vascular leakage in diabetic mice. (Sugimoto et al., 2013). These findings provide 
unique insight into the role of insulin signaling in mediating retinal effects in diabetes 
and the role of EGF signaling in the pathogenesis of Diabetic Retinopathy.  
 
 
Figure 58. Activation of EGF-R and the downstream Ras-Raf-MAP kinase pathway or PI3K-Akt pathway 
leads to altered cell proliferation, angiogenesis, and anti-apoptosis. 
The last two functions are further enhanced by the E5-induced upregulation of COX-2 expression. COX-2 
activates VEGF leading to angiogenesis. Dotted arrow shafts indicate uncertain pathways. Adapted from 
Venuti et al., 2011. 
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After variant validation and literature review, a table with all 40 samples, the 
candidate common variants and associated genotypes was constructed (Figure 59). 
 
Figure 59. Genotypes of all 40 patients for the 11 common variants grouped by: without DR (ETDR values 
≤20) and with DR (ETDR values >20). 
The protective variants are highlighted in green and the risk variants in red. The altered homozygous 
genotypes are in turquoise and the altered heterozygous genotypes in yellow. 
 
The overall genotype distribution is quite clear with the highlight of two major 
groups: risk variants vs protective variants and T2D with DR vs T2D without DR. There 
seems to be a larger incidence of homozygotes in the risk variants and the question 
remains as if it would be possible to create genetic profiles that could explain the 
excess risk of developing Diabetic Retinopathy or even if there are certain genetic 
profiles that could explain why some individuals, although diagnosed with T2D for 
many years, still don't present signs of the microvascular complication. Clearly this 
would have to be applied to a larger population as well as a thorough study and 
determination regarding the real implication of these candidate variants as genetic 
markers for Diabetic Retinopathy. 
  
AGER ITGA1 MMP1 TNFSF12 IOP1 PLXDC1 PRKCQ GSTM3 EGF
G/A T/A T/C G/A A/G C/T G/A G/A C/G C/T T/A
ETDR value rs1035798 rs62357156 rs7125062 rs80067372 rs4434138 rs4234633 rs10794640 rs9907595 rs2296123 rs7843 rs4698803
Ex1 w/out DR G/G T/T T/T G/A A/G C/T G/A G/G G/G C/T T/T
Ex13 w/out DR G/G T/T T/T G/G A/A C/C G/A G/G C/C C/C T/T
Ex19 w/out DR G/G T/T T/T G/G A/G C/T A/A A/G C/G T/T A/A
Ex21 w/out DR G/G T/T T/C G/A A/A C/C G/G G/G C/G C/C A/T
Ex28 w/out DR G/A T/A T/T G/G A/G C/T G/G A/A G/G C/C A/T
Ex35 w/out DR G/G T/T T/T G/G A/A C/C G/A G/G C/G C/C T/T
Ex36 w/out DR G/G T/T T/T G/A A/A C/C G/G A/G C/G C/T T/T
Ex38 w/out DR G/A T/T T/C G/G A/G C/T G/G A/G C/G T/T T/T
Ex44 w/out DR G/G T/T T/T G/G A/A C/C G/G G/G C/G C/C T/T
Ex50 w/out DR G/A T/T T/C G/G A/G C/T G/G A/G G/G C/T A/A
Ex6 w/out DR G/G T/T T/T G/G G/G T/T G/G A/G C/G T/T A/T
Ex16 w/out DR G/A T/T T/T G/A A/G C/T G/A A/G G/G C/C T/T
Ex18 w/out DR G/G T/T T/T G/A A/G C/T G/A A/G G/G C/C T/T
Ex27 w/out DR G/A T/A T/T G/A ./. C/C G/G G/G C/G T/T T/T
Ex29 w/out DR G/G T/T T/T G/G A/A C/C G/A A/G C/C T/T A/A
Ex45 w/out DR G/G T/T T/T G/G A/G C/T G/A A/G C/G C/T A/T
Ex39 ETDR = 20 G/G T/T T/C G/A A/G C/T G/G G/G C/G C/C T/T
Ex40 ETDR = 20 G/A T/T T/C G/A A/G C/T G/G G/G C/C C/T T/T
Ex42 ETDR = 25 G/G T/A T/T G/G G/G T/T G/G G/G C/G C/C T/T
Ex11 ETDR = 35 A/A T/A C/C G/A G/G T/T G/G G/G C/C C/C T/T
Ex12 ETDR = 35 G/G T/A C/C G/A G/G T/T G/G G/G C/C C/T T/T
Ex24 ETDR = 35 G/A T/T T/T A/A A/A C/C G/G G/G C/C C/T A/T
Ex26 ETDR = 35 G/A T/A T/T G/G A/G C/T G/G G/G C/G C/C T/T
Ex30 ETDR = 35 G/A A/A T/C G/A G/G T/T G/G G/G C/G C/T T/T
Ex4 ETDR = 35 G/G T/A T/C G/G A/G C/T G/G G/G C/C C/T T/T
Ex46 ETDR = 35 G/A T/T T/T G/A G/G C/T G/G G/G C/C C/C T/T
Ex47 ETDR = 35 G/A T/A T/T G/A A/G C/T G/G G/G C/C C/T T/T
Ex9 ETDR = 35 G/A T/A T/C G/A A/A C/C G/G G/G C/C C/C T/T
Ex17 ETDR = 43 G/A T/A T/C G/A G/G T/T G/G A/G C/C C/C T/T
Ex2 ETDR = 43 G/A T/A T/T G/A A/G C/T G/G G/G G/G C/C T/T
Ex33 ETDR = 43 G/A T/A T/T G/A G/G T/T G/G A/G C/G C/C T/T
Ex34 ETDR = 43 G/G T/A T/C G/G A/G C/T G/G G/G C/C C/T T/T
Ex37 ETDR = 43 G/G T/T C/C G/A A/G C/T G/G A/G C/G C/C A/T
Ex41 ETDR = 43 G/A T/T T/T G/A A/G C/T G/G G/G C/C C/C T/T
Ex43 ETDR = 47 G/A T/T T/T G/A G/G T/T G/G A/G C/G C/C T/T
Ex48 ETDR = 53 A/A T/A C/C G/G G/G T/T G/G G/G C/C C/C T/T
Ex49 ETDR = 53 G/A T/A T/C A/A G/G T/T G/G G/G C/C C/T T/T
Ex10 ETDR = 90 G/A T/T T/C A/A G/G T/T G/A G/G C/G C/C T/T
Ex23 ETDR = 90 G/A T/A T/C G/G A/G C/T G/G G/G C/G C/T T/T
Ex7 ETDR = 90 G/A T/T T/C G/A A/G C/T G/A G/G C/G C/T A/T
Protective Variants
Risk Variants
Altered Homozygous
Altered Heterozygous
Genes Comuns
STAB1
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4. Conclusions and Future Work 
 
This study sought to identify candidate genetic markers that could explain the 
excess risk associated to the onset of Diabetic Retinopathy, a complication in which 
diabetes duration and glycemic control, are major contributors to development and 
progression.  
The Ion Torrent technology and Whole Exome Sequencing protocol used 
revealed being an efficient procedure for the detection of variants with a potential 
relevance to the complication. In conclusion of all the technical work done in this 
study, we can clearly state that Whole Exome Sequencing is a valid and complete way 
of obtaining a large quantity of information in an extended group of genes. This 
information spans the coding region of the genome and thus increases the possibilities 
in finding variants, common and rare, that may be considered as candidate without 
prior knowledge of which genes to look for. The vast majority of variants encountered 
in the exomes and further studied were real and correctly called. For that, all the 
filtering procedures and in-house scripts used were essential to guarantee the quality 
and veracity of the variants identified. The variants identified in the exomes were all 
validated by other technologies.  
The search for rare variants, led to the identification of 10 genes accumulating 
rare variants: DMXL2, E2F8, DNASE1L2, MAML3, ADAMTS2, EP300, CASZ1, APCDD1L, 
S100A14 and GPR142 that were potentially relevant and related to mechanisms and 
pathways responsible for the pathogenesis of the complication. Some of these genes 
seem to be linked to the presence of DR, whereas other genes seem to be linked to the 
progression of DR and were thus associated to more severe forms of Diabetic 
Retinopathy. It seems that aggravated DR (ETDR values near 90) is related to more rare 
variant accumulation and these seem related to specific genes. 
The search for common variants led to the identification of 11 variants: 
rs1035798, rs62357156, rs7125062, rs80067372, rs4434138, rs4234633, rs10794640, 
rs9907595, rs2296123, rs7483 and rs4698803 in 10 genes: AGER, ITGA1, MMP1, TNFSF12, 
STAB1, NARFL, PLXDC1, PRKCQ, GSTM3 and EGF. Of these, only AGER has been consistently 
found as associated to Diabetic Retinopathy. All the genes considered relevant are in some 
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way related to the mechanism and pathways documented in the literature as being associated 
to DR. In fact, literature review was the criteria for relevance determination of the genes.  The 
mechanisms in which these variants seem to participate or have been documented as being 
related were: Advanced Glycated End (AGE) products trafficking and signaling pathway, 
fibrovascular membrane formation, EGF-VEGF signaling pathway, VEGFA-dependent 
angiogenesis, vascular assembly and morphogenesis and the Notch signalling pathway.  
The rare variant accumulating gene approach identified several other genes with an 
elevated statistical significance, giving our population number, besides the explored E2F8, and 
DMXL2 genes. However, with the present knowledge it is difficult to associate or even 
understand the role of these genes and their genetic significance to DR. 
This study identified new candidate variants/genes that may reveal useful, in the 
future, for the understanding of the complication. 
As future work we propose that the genes that accumulate rare variants but for 
which there is still no association to the disease, be studied in detail and this gene wise 
burden approach be applied to the protective rare variant accumulating genes. 
We also propose the extension of this study to a much larger population and 
that these genes and variants be functionally explored. 
The results of this study open the possibility to the determination of genetic 
profiles that may determine the onset of DR in certain patients, be that of risk variants, 
which could explain why patients that have T2D for 5 or 6 years and a tight glycemic 
control, present DR or of protective variants, explaining the cases of T2D patients that 
have the complex disease for more than 20 years, do not seem to control their 
glycemic levels and still do not present DR. 
This fundaments the notion that DR onset has environmental factors that may 
delay or even attenuate progression and development but genetic factors are also very 
preponderant.  
 
  
 86 
 
  
 87 
 
 
Bibliography 
 
  
 88 
 
Bibliography  
Abhary, S., Hewitt, A., Burdon, K. & Craig, J. (2009). A Systematic Meta-Analysis of Genetic 
Association Studies for Diabetic Retinopathy. Diabetes, Vol 58, pp. 2137-2147. 
Albrechtsen A, Grarup N, Li Y, Sparsø T, Tian G, Cao H, Jiang T, Kim SY, Korneliussen T, Li Q, 
Nie C, Wu R, Skotte L, Morris AP, Ladenvall C, Cauchi S, Stančáková A, Andersen G, Astrup A, 
Banasik K, Bennett AJ, Bolund L, Charpentier G, Chen Y, Dekker JM, Doney AS, Dorkhan M, 
Forsen T, Frayling TM, Groves CJ, Gui Y, Hallmans G, Hattersley AT, He K, Hitman GA, Holmkvist 
J, Huang S, Jiang H, Jin X, Justesen JM, Kristiansen K, Kuusisto J, Lajer M, Lantieri O, Li W, Liang 
H, Liao Q, Liu X, Ma T, Ma X, Manijak MP, Marre M, Mokrosiński J, Morris AD, Mu B, Nielsen 
AA, Nijpels G, Nilsson P, Palmer CN, Rayner NW, Renström F, Ribel-Madsen R, Robertson N, 
Rolandsson O, Rossing P, Schwartz TW; D.E.S.I.R. Study Group, Slagboom PE, Sterner M; 
DIAGRAM Consortium, Tang M, Tarnow L, Tuomi T, van't Riet E, van Leeuwen N, Varga TV, 
Vestmar MA, Walker M, Wang B, Wang Y, Wu H, Xi F, Yengo L, Yu C, Zhang X, Zhang J, Zhang Q, 
Zhang W, Zheng H, Zhou Y, Altshuler D, 't Hart LM, Franks PW, Balkau B, Froguel P, McCarthy 
MI, Laakso M, Groop L, Christensen C, Brandslund I, Lauritzen T, Witte DR, Linneberg A, 
Jørgensen T, Hansen T, Wang J, Nielsen R, Pedersen O. (2013). Exome sequencing-driven 
discovery of coding polymorphisms associated with common metabolic phenotypes. 
Diabetologia 56:298-310. 
 
Ameri, H., Liu, H., Liu, R., Ha, Y., Paulucci-Holthauzen, A., Hu, S., Motamedi, M., Godley, B., 
Tilton, R. and Zhan, W. (2014). TWEAK/Fn14 Pathway Is a Novel Mediator of Retinal 
Neovascularization. Investigative Ophthalmology & Visual Science, Vol. 55, No. 2, 802-813 
 
American Diabetes Association. 2014. Estimates of Diabetes and Its Burden in the 
Epidemiologic estimation methods. National Diabetes Statistics Report, pp.2009–2012. 
 
Anomalies, M. and Brief, P. (2003). Type 2 Diabetes and Genetic Technology: A Policy Brief; 
Washington State Department of Health 
 
Arboleda-Velasquez, JF, Primo V, Graham M, James A, Manent J, D'Amore PA (2014). Notch 
Signaling functions in retinal pericyte survival. Investigative Ophthalmology & Visual Science, 
55: 5191-5199 -  
 
Askari, J., Buckley, P., Mould, A. and Humphries, M. (2009). Linking integrin conformation to 
function. Journal of Cell Science, 122 (2), pp.165-170 
 
Austin, K., Covic, L and Kulipulos, A. (2013). Matrix metalloproteases and PAR1 activation. 
Blood, Volume 121, Number 3 pp. 431-439 
 
Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA and Shendure J (2011) 
Exome sequencing as a tool for Mendelian disease gene discovery. Nature Reviews GENETICS; 
Volume 12; 745-755 
 
Barroso, I., Luan, .J, Middelberg, R., Harding, A,. Franks, P., Jakes, R., Clayton, D., Schafer, A., 
O’Rahilly, S. and Wareham, N. (2003). Candidate Gene Association Study in Type 2 Diabetes 
Indicates a Role for Genes Involved in β-Cell Function as Well as Insulin Action. PLoS Biology, 
Volume 1, Issue 1; pp 441-445 
 89 
 
 
Beltramo, E and Porta, M. (2013). Pericyte loss in Diabetic Retinopathy: Mechanisms and 
Consequences. Current Medicinal Chemistry, 20, pp 3218-3225 
 
Bloomgarden, Z. (2004). Type 2 Diabetes in the Young: The Evolving Epidemic. Diabetes 
Care, Volume 27, Number 4; pp. 998-1010. 
 
Bonnefond A, Durand E, Sand O, De Graeve F, Gallina S, Busiah K, Lobbens S, Simon A, 
Bellanné-Chantelot C, Létourneau L, Scharfmann R, Delplanque J, Sladek R, Polak M, Vaxillaire 
M and Froguel P. (2010). Molecular Diagnosis of Neonatal Diabetes Mellitus Using Next-
Generation Sequencing of the Whole Exome. PLoS ONE; Volume 5, Issue 10, e13630; pg.1-5 
 
Bush, W. and Moore, J. (2012). Chapter 11: Genome-Wide Association Studies. PLOS 
Computational Biology, Vol 8, Issue 12, e1002822. 
 
Charpentier MS, Christine KS, Amin NM, Dorr KM, Kushner EJ, Bautch VL, Taylor JM, Conlon 
FL. (2013). CASZ1 promotes vascular assembly and morphogenesis through the direct 
regulation of an EGFL7/RhoA-mediated pathway. Development Cell. 25(2):132-43.  
 
Chen Y, Cunningham F, Rios D, McLaren WM, Smith J, Pritchard B, Spudich GM, Brent S, 
Kulesha E, Marin-Garcia P, Smedley D, Birney E, Flicek P. (2010). Ensembl variation resources. 
BMC Genomics. 11:293. 
 
Chen, P., Ong, R., Tay, W.,Sim, X., Ali, M., Xu, H., Suo, C., Liu, J., Chia, K., Vithana, E., Young, 
T., Aung, T., Lim, W., Khor, C., Cheng, C., Wong, T., Teo, Y. and Tai, E. (2013). A Study Assessing 
the Association of Glycated Hemoglobin A1C (HbA1C) Associated Variants with HbA1C, Chronic 
Kidney Disease and Diabetic Retinopathy in Populations of Asian Ancestry. PLOSOne, Volume 8 
Issue 11, e79767 
 
Chung, A. & Ferrara N. (2010). The Extracellular Matrix & Angiogenesis: Role of the 
Extracellular Matrix in Developing Vessels and Tumor Angiogenesis. www.sabiosciences.com. 
Pathways, Issue #11.  
 
Cooper, G., Stone, E., Asimenos, G., NISC Comparative Sequencing Program, Green, E., 
Batzoglou, S., and Sidow, A. (2005). Distribution and intensity of constraint in mammalian 
genomic sequence. Genome Research, 15(7):901-13  
 
Cunningham, F., M. Ridwan Amode, Daniel Barrell, Kathryn Beal, Konstantinos Billis, Simon 
Brent, Denise Carvalho-Silva, Peter Clapham, Guy Coates, Stephen Fitzgerald, Laurent Gil, 
Carlos Garcín Girón, Leo Gordon, Thibaut Hourlier, Sarah E. Hunt, Sophie H. Janacek, Nathan 
Johnson, Thomas Juettemann, Andreas K. Kähäri, Stephen Keenan, Fergal J. Martin, Thomas 
Maurel, William McLaren, Daniel N. Murphy, Rishi Nag, Bert Overduin, Anne Parker, Mateus 
Patricio, Emily Perry, Miguel Pignatelli, Harpreet Singh Riat, Daniel Sheppard, Kieron Taylor, 
Anja Thormann, Alessandro Vullo, Steven P. Wilder, Amonida Zadissa, Bronwen L. Aken, Ewan 
Birney, Jennifer Harrow, Rhoda Kinsella, Matthieu Muffato, Magali Ruffier, Stephen M.J. 
Searle, Giulietta Spudich, Stephen J. Trevanion, Andy Yates, Daniel R. Zerbino and Paul Flicek 
(2015). Ensembl 2015. Nucleic Acids Research 43 Database issue:D662-D669  
 
Danecek, P., Auton, A., Abecasis;G., Albers, C., Banks, E., DePristo, M., Handsaker, R., Lunter, 
G., Marth, G., Sherry, S., McVean, G., Durbin, R. and 1000 Genomes Project Analysis Group. 
(2011). The variant call format and VCFtools. Bioinformatics Applications Note, Vol. 27 no. 15, 
pages 2156–2158 
 90 
 
 
Do, R., Kathiresan, S. and Abecasis, G. (2012). Exome sequencing and complex disease: 
practical aspects of rare variant association studies. Human Molecular Genetics, Vol. 21, 
Review Issue 1; R1-R9. 
 
Doria, A. (2010). Genetics of Diabetes Complications. Current Diabetes Reports, 10 (6): 467-
475. 
 
Droumaguet, C., Balkau, B., Simon, D., Caces, E., Tichet, J., Charles, M., Eschwege, E and The 
DESIR Study group. (2006). Use of HbA1c in Predicting Progression to Diabetes in French Men 
and Women. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). 
Diabetes Care, Volume 29, Number 7 
 
Dunham, I. et al., (2012). An integrated encyclopedia of DNA elements in the human 
genome. Nature, 2012 Sep 6; 489(7414):57-74.  
 
Eichler, E., Flint, J., Gibson, G., Kong, A., Leal, S., Moore, J and Nadeau, J. (2010). Missing 
Heritability and Strategies for finding the underlying causes of complex disease. Nat. Rev. 
Genet. 2010 Jun, 11(6): 446-450 
 
El-Asrar, A., Mohammad, G., Nawaz, M., Siddiquei, M., Van den Eynde, K., Mousa, A., De 
Hertogh, G. and Opdenakker, G. (2013). Relationship between Vitreous Levels of Matrix 
Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic 
Retinopathy. PLOS ONE, Volume 8, Issue 12, e 85857 
 
Estrada, K. (2013). Whole-exome sequencing of 4,000 samples identifies rare variants 
strongly associated with type 2 diabetes risk in Mexicans and Latinos. (Abstract) American 
Society of Human Genetics, Annual Meeting, Boston, October 22-26 
 
Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA 
 
Falcão, M., Falcão-Reis, F. & Rocha-Sousa, A. (2010). Diabetic Retinopathy: Understanding 
Pathogenic Angiogenesis and Exploring its Tratment Options. the Open Circulation and 
Vascular Journal, 3, 30-42. 
 
Fong, D., Aiello, L., Gardner, T., King, G., Blankenship, G., Cavallerano, J., Ferris, F., Klein, R. 
(2004). Retinopathy in Diabetes. Diabetes Care, Vol. 27, Supplement 1, S84-S87. 
 
Frazer, K. Murray, S., Schork, N. & Topol, E. (2009). Human genetic variation and its 
contribution to complex traits. Nature reviews. Genetics, 10(4), pp.241–251. 
 
Fredriksson R, Höglund PJ, Gloriam DE, Lagerström MC, Schiöth HB. (2003). Seven 
evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. 
FEBS Lett. 2003 Nov 20;554(3):381-8 
 
Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ. (2002). Structural 
basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc. Natl. Acad. Sci. 
U.S.A. 2002; 99(8);5367-72 . 
 
Gaudet, M., Giulia, F., Beritognolo, I and Sabatti, M. (2009). Allele-Specific PCR in SNP 
Genotyping Single Nucleotide Polymorphisms Methods in Molecular Biology, Volume 578, 
2009, pp 415-424  
 91 
 
 
Ghosh, A., Shanafelt, T., Cimmino, A., Taccioli, C., Volinia, S., Liu, C., Calin, G., Crove, C., 
Chan, D., Giaccia, A., Secreto, C., Wellik, L., Lee, Y., Mukhopadhyay, D and Kay, N. (2009). 
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. 
Blood, 28. Volume 113, number 22, pp.5568-5574. 
 
Gilissen, C., Hoischen, A., Brunner, H.  and Veltman, J. (2011). Unlocking Mendelian disease 
using exome sequencing. Genome Biology, 12:228-238 
 
Goldin A, Beckman JA, Schmidt AM, Creager MA. (2006). Advanced glycation end products: 
Sparking the development of diabetic vascular injury. Circulation, 114(6), pp.597–605.  
 
Gotzaridis, E., Markou, A. and Gregor, Z. (2004).Management of Diabetic Retinopathy. An 
Overview. Hormones, 3 (2):92-99 
 
Hammes. H., Lin, J., Renner, O., Shani, M., Lundqvist, A., Betsholtz, C., Brownlee, M and 
Deutsch, U. (2002). Pericytes and the Pathogenesis of Diabetic Retinopathy. Diabetes, Vol. 
51:3107-3112. 
 
Heo, F. , Fujiwara, K. and  Abe, J. (2011). Disturbed-flow-mediated vascular reactive oxygen 
species induce endothelial dysfunction. Circ J. 2011;75(12):2722-30 
 
Huang, J., Song, D., Flores, A., Zhao, Q., Mooney, S., Shaw, L., and Lee, F. (2007). IOP1, a 
novel hydrogenase-like protein that modulates hypoxia-inducible factor-1α activity. Biochem. 
J., 401:341-352. 
 
Johansson S, Irgens H, Chudasama KK, Molnes J, Aerts J, Roque FS, Jonassen I, Levy S, Lima 
K, Knappskog PM, Bell GI, Molven A and Njølstad PR (2012). Exome Sequencing and Genetic 
Testing for MODY. PLoS ONE; Volume 7, Issue 5, e38050; pp.1-7 
 
Jin, Q., Chen, H., Luo, A, Ding, F and Liu, Z. (2011). S100A14 Stimulates Cell Proliferation and 
Induces Cell Apptosis at Different Concentrations via Receptor for Advanced Glycation End 
Products (RAGE). PLOSOne, Vol, 6, Issue 4, e19375. 
Kahn, C. (1994). Banting Lecture. Insulin Action, Diabetogenes, and the Cause of Type II 
Diabetes; DIABETES, vol 43; pg.1066-1084 
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., and Tanabe, M. (2014). Data, 
information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, 
D199–D205. 
 
Kanehisa, M. and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. 
Nucleic Acids Res. 28, 27-30. 
 
Kang, H. et al., (2010). Variance component model to account for sample structure in 
genome-wide association studies. Nature genetics, 42(4), pp.348–354. 
 
Kang, H., Zhan, X. Sim, C. (2012). EPACTS : A flexible and efficient sequence-based genetic 
analysis software package. Biostatistics Dept, University of Michigan, Ann Arbor, Ann Arbor, 
MI., meeting 2012 
 
 92 
 
Kiezun, A., Garimella, K., Do, R., Stitziel, N., Neale, B., McLaren, P., Gupta, N., Sklar, P., 
Sullivan, P., Moran, J., Hultman, C., Lichtenstein, P., Magnusson, P., Lehner, T., Shugart, Y., 
Price, A., de Bakker, P., Purcel, S and Sunyaev, S. (2012). Exome Sequencing and and the 
genetic basis of complex traits. Nature Genetics, volume 44 number 6, 623-630 
 
Kishore , P. (2013). "Diabetes Mellitus (DM)" The Merck Manual for Health Care 
Professionals 
http://www.merckmanuals.com/professional/endocrine_and_metabolic_disorders/diabetes_mellitus_a
nd_disorders_of_carbohydrate_metabolism/diabetes_mellitus_dm.html#v988257 (Last full 
review/revision December 2012, Content last modified October 2013). 
 
Koeleman BPC, Al-Ali A, Van der Laan SW and Asselbergs FW (2013). A Concise History of 
Genome-Wide Association Studies. Saudi Journal of Medicine & Medical Sciences; Vol.1, Issue 
1; pg. 4-10 
 
Kuo, J., Wong, T. and Rotter, J. (2014). Challenges in elucidating the genetics of diabetic 
retinopathy. JAMA Ophthalmology, 132(1):96-107. 
 
Kzhyshkowska, J., Workman, G., Cardó -Vila, M., Arap, W., Pasqualini, R., Gratchev, A., 
Krusell, L., Goerdt, S., and Sage, E. (2006). Novel Function of Alternatively Activated 
Macrophages: Stabilin-1-Mediated Clearance of SPARC. The Journal of Immunology, 176: 
5825–5832. 
 
Kzhyshkowska, J. (2010). Multifunctional Receptor Stabilin-1 in Homeostasis and Disease. 
The Scientific World Journal, 10: 2039-2053. 
 
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. (2014). 
ClinVar: public archive of relationships among sequence variation and human phenotype. 
Nucleic Acids Res. 2014 Jan 1;42(1):D980-5. 
 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., 
Durbin, R., and 1000 Genome Project Data Processing Subgroup. (2009). The Sequence 
Alignment/Map format and SAMtools. Bioinformatics Applications Note, Vol. 25 no. 16, pages 
2078–2079 
 
Life Technologies Release (2012). Exome sequencing using the Ion Proton System. Proton 
Exome Sequencing Product Bulletin 
 
Lin, S., Oyama, L., Nagase, T., Harigaya, K. and Kitagawa, M. (2002). Identification of new 
human mastermind proteins defines a family that consists of positive regulators for Notch 
signaling.Journal of Biological Chemistry, 277: 50612-50620. 
 
Lohmueller, K., Sparsø T., Li, Q., Andersson, E., Korneliussen, T., Albrechtsen, A., Banasik K., 
Grarup, N., Hallgrimsdottir, I., Kiil, K., Kilpelainen, T.,  Krarup, N., Pers T., Sanchez, G., Hu Y., 
DeGiorgio, M., Jørgensen, T., Sandbæk, A., Lauritzen, T., Brunak S., Kristiansen, K., Li Y., 
Hansen, T., Wang, J., Nielsen, R. and Pedersen, R. (2013). Whole-Exome Sequencing of 2,000 
Danish Individuals and the Role of Rare Coding Variants in Type 2 Diabetes. The American 
Journal of Human Genetics, 93: 1072-1086. 
 
Lyssenko, V., Almgren, P., Anevsk,i D., Orho-Melander, M., Sjogren, M., Saloranta, C., Tuomi, 
T., Groop, L. and the Botnia Study Group. (2005). Genetic Prediction of Future Type 2 Diabetes. 
PLoS MEDICINE; Volume 2, Issue 12, e345; pg.1299-1308 
 93 
 
 
Lyssenko, V. and Laakso, M. (2013). Genetic Screening for the Risk of Type 2 Diabetes: 
Worthless or valuable?. DIABETES CARE, Volume 36, Supplement 2, S120-S126 
 
Madsen-Bouterse, S and Kowluru, R. (2008). Oxidative stress and diabetic retinopathy: 
Pathophysiological mechanisms and treatment perspectives. Reviews in Endocrine and 
Metabolic Disorders, Volume 9, Issue 4,pp.315-327. 
 
Maes, C. Carmeliet, G and Schipani, E. (2012). Hypoxia-driven pathways in bone 
development, regeneration and disease Nature. Reviews. Rheumatology, 8, pp. 258-266 
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos 
EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, 
Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, 
Mackay TF, McCarroll SA and Visscher PM. (2009) Finding the missing heritability of complex 
diseases”; Nature. 2009 October 8; 461(7265):747-753. DOI: 10.1038/nature08494 
 
Marian, A. (2012). Molecular Genetic Studies of Complex Phenotypes. Translational 
Research, 159(2): 64–79. doi:10.1016/j.trsl.2011.08.001 
 
Marth, G., Yu, F., Indap, A., Garimella, K., Gravel, S., Leong, W., Smith, C., Bainbridge, M., 
Blackwell, T., Bradley, X., Chen, Y., Challis, D., Clarke, L., Ball, E., Cibulskis, K., Cooper, D., 
Fulton, B., Hartl, C., Koboldt, D., Muzny, D., Smith, R., Sougnez, C., Stewart, C., Ward, A., Yu, J., 
Xue, Y., Altshuler, D., Bustamante, C., Clark, G., Daly, M., DePristo, M., Flicek, P., Gabriel, S., 
Mardis, E., Palotie, A., Gibbs, R. and the 1000 Genomes Project. (2011). The functional 
spectrum of low-frequency coding variation. Genome Biology, 12:R84 
 
Martinez, R.(2013). Prevalence of Diabetes in the World, 2013. Health Intelligence. Nov 18. 
 
Massi-Benedetti, M. (2002). The Cost of Diabetes Type II in Europe: The CODE-2 Study; 
Diabetologia, 45 (7):S1-S4.  
 
Mathers, C. and Loncar, D. (2006). Projections of Global Mortality and Burden of Disease 
from 2002 to 2030. PLoS Medicine, November 2006, Volume 3, Issue 11, e442 
 
McLaren, W. et al., (2010). Deriving the consequences of genomic variants with the Ensembl 
API and SNP Effect Predictor. Bioinformatics, 26(16), pp.2069–2070. 
 
1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin 
RM, Handsaker RE, Kang HM, Marth GT, McVean GA (2012). An integrated map of genetic 
variation from 1,092 human genomes. Nature 491, 56–65  
 
Morris, A., Voight, B. And Teslovich, T. (2012). Large-scale association analysis provides 
insights into the genetic architecture and pathophysiology of type 2 diabetes. NATURE 
GENETICS, 2012 September; 44(9):981-990.  
 
Motte, P., Deroanne, C., Colige, A., Lambert, V., Nusgens, B., Lapi, C., Rakic, J., Dubail, J. and 
Kesteloot, F. (2010). ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule 
independently of its catalytic activity. Cell Mol Life Sci. Vol 67 (4213-4232) 
 
 94 
 
Ng, D. (2010). Human Genetics of Diabetic Retinopathy: Current Perspectives. Journal of 
Ophthalmology, Vol 2010, Article ID 172593. 
 
Ola, M. & Nawaz, M. (2012). Cellular and Molecular Mechanism of Diabetic Retinopathy. 
Diabetic Retinopathy, Chapter 1. Dr. Mohammad Shamsul Ola (Ed.), ISBN: 978-953-51-0044-7, 
 
Olokoba, A., Obateru, O and Olokoba, L.  (2012). Type 2 Diabetes Mellitus: A review of 
Current Trends. Oman Medical Journal, Vol.27, No. 4:269-273. 
 
Organização Nacional da Diabetes. (2014). Diabetes: Factos e Números 2014. Relatório 
Anual do Observatório Nacional da Diabetes 
 
Ozturk, B., Bozkurt, B., Kerimoglu, H., Okka, M., Kamis, U. and Gunduz, K. (2009). Effect of 
serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Molecular 
Vision, 15:1906-1914 
 
Paila, U., Chapman, B., Kirchner, R., Quinlan, A. (2013). GEMINI: Integrative Exploration of 
Genetic Variation and Genome Annotations. PLoS Comput Biol 9(7): e1003153. 
 
Panoutsopoulou, K., Tachmazidou, I. & Zeggini, E., (2013). In search of low-frequency and 
rare variants affecting complex traits. Human Molecular Genetics, 22(R1), pp.16–21. 
 
Park,J., Park,Y., Jung, W., Lee, J. and Lee, J. (2014). Microarray Analysis for Genes Associated 
with Angiogenesis in Diabetic OLETF Keratocytes . J Korean Med Sci. 2014 Feb; 29(2): 265–271. 
 
Prasad, T., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., Telikicherla, 
D., Raju, R., Shafreen, B., Venugopal, A., Balakrishnan, L., Marimuthu, A., Banerjee, S., 
Somanathan, D., Sebastian, A., Rani, S., Ray, S., Kishore, C., Kanth, S., Ahmed, M., Kashyap, M., 
Mohmood, R., Ramachandra, Y., Krishna, V., Rahiman, A., Mohan, S., Ranganathan, P., 
Ramabadran, S., Chaerkady, R. and Pandey, A. (2009). Human Protein Reference Database - 
2009 update. Nucleic Acids Research. 37, D767-D772 
 
Rabbani, B., Tekin, M. and Mahdieh, N. (2014) The promise of whole-exome sequencing in 
medical genetics. Review. Journal of Human Genetics, 59: 5–15 
 
Reis, A. And Velho, G. (2002). Bases Genéticas do Diabetes Mellitus Tipo 2. Arquivos 
Brasileiros de Endocrinolagia e Metabologia, Vol 46, nº4; pg. 426-432 
 
Roca, C and Adams, R. (2007). Regulation of vascular morphogenesis by Notch siganling. 
Genes and Development, 21:2511-2524. 
 
Rothberg, J. et al, (2011). An integrated semiconductor device enabling non-optical genome 
sequencing. Nature  475, 348–352 
 
Safi, S., Qvist, R., Kumar, S., Batumalaie, K and Ismail, I. (2014). Molecular Mechanisms of 
Diabetic Retinopathy, General Preventive Strategies and Novel Therapeutic Targets. 
BioMedical Research International, Volume 2014, Article ID 801269. 
 
Sethi, N., Yan, Y., Quek, D., Schupbach, T and Kang, Y. (2010). Rabconnectin-3 is a functional 
regulator of Mammalian Notch Signaling. Journal of Biological Chemistry, Vol 285, no. 
45:34757-34764  
 
 95 
 
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K.(2001). dbSNP: 
the NCBI database of genetic variation. Nucleic Acids Res. 2001 Jan 1;29 (1):308-11. 
 
Shiokawa, D., Matsushita, T., Kobayashi, T, Matsumoto, Y & Tanuma, S. (2004). 
Characterization of the human DNASE1L2 gene and the molecular mechanism of its 
transcriptional activation induced by inflammatory cytokines. Genomics, 84: 95-105. 
 
Shyr C, Tarailo-Graovac M, Gottlieb M, Lee J, van Karnebeek C, Wasserman W. (2014). 
FLAGS, frequently mutated genes in public exomes. BMC Medical Genomics, 7:64. 
 
Simbolo, M., Gottardi, M., Corbo, V., Fassan, M., Mafficini, A., Malpeli, G., Lawlor, R. and 
Scarpa, A. (2013). DNA Qualification Workflow for Next Generation Sequencing of 
Histopathological Samples. PLOS One, Volume 8, Issue 6: e62692 
 
Sugimoto, M., Cutler, A., Shen, B., Moss, S., Iyengar, S., Klein, R., Folkman, J. amd Anand-
Apte, B. (2013).Inhibition of EGF Signaling Protects the Diabetic Retina from Insulin-Induced 
Vascular Leakage The American Journal of Pathology, Vol 183, No. 3 pp.987-995 
 
Tabernero, J. (2007). The Role of VEGF and EGFR Inhibition: Implications for Combining 
Anti–VEGF and Anti–EGFR Agents. Molecular Cancer Research, Vol 5(3)pp203-217. 
 
Tamura, Y., Adachi, H., Osuga, J., Ohashi, K., Yahagi, N., Sekiya, M., Okazaki, H., Tomita, S., 
Iizuka, Y., Shimano, H., Nagai, R., Kimura, S., Tsujimoto, M. and Ishibashi, S. (2003). FEEL-1 and 
FEEL-2 Are Endocytic Receptors for Advanced Glycation End Products. The Journal Of Biological 
Chemistry, Vol. 278, No. 15, Issue of April 11, pp. 12613–12617, 2003 
 
Tang, Z., Fang, Z and Zhou, L. (2013). Human Genetics of Diabetic Vascular Complications. 
Journal of Genetics, Vol 92, No.3. 
 
Tarr, J., Kaul, K., Chopra, M., Kohner, E. and Chibber, R. (2013). Pathophysiology of Diabetic 
Retinopathy. ISRN Ophthalmology, Article ID 343560. 
 
van den Oever, I., Raterman, H., Nurmohamed, M & Simsek, S. (2010). Endothelial 
Dysfunction, Inflammation and Apoptosis in Diabetes Mellitus. Mediators of Inflammation, 
Volume 2010,Article ID 792393. 
 
van Dijk, E., Auger, H., Jaszczyszyn, Y . and Thermes, C. (2014). Ten Years of Next-Generation 
Sequencing Technology. Trends in Genetics, Vol. 30, No. 9, pp. 418-426 
 
Venuti, A., Paolini, F., Nasir, L., Corteggio, A., Roperto, S., Campo, M. and Borzacchiello, G. 
(2011). Papillomavirus E5; the smallest oncoprotein with many functions. Molecular Cancer, 
10:140 
 
Wang, Z., Liu, X., Yang, B. Z. and  Gelernter, J. (2013). The role and challenges of exome 
sequencing in studies of human diseases. Review Article. Frontiers in Genetics, Vol 4, Article 
160. 
 
Weedon, M., McCarthy, M., Hitman, G., Walker, M,. Groves, C., Zeggini, E., Rayner, N., 
Shields, B., Owen, K., Hattersley, A. and Frayling, T. (2006). Combining Information from 
Common Type 2 Diabetes Risk Polymorphisms Improves Disease Prediction. PLoS MEDICINE; 
Volume 3, Issue 10, e374; pg. 1877-1882 
 
 96 
 
Warpeha, K. & Chakravarthy, U. (2003). Molecular genetics of microvascular disease in 
diabetic retinopatht. Eye, 17, 305-311. 
 
Weijts BG1, Bakker WJ, Cornelissen PW, Liang KH, Schaftenaar FH, Westendorp B, de Wolf 
CA, Paciejewska M, Scheele CL, Kent L, Leone G, Schulte-Merker S, de Bruin A. (2012). E2F7 and 
E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with 
HIF1A. The EMBO Journal, 31, 3871-3884. 
 
Wu, J., Li, Y. & Jiang, R. (2014). Integrating Multiple Genomic Data to Predict Disease-
Causing Nonsynonymous Single Nucleotide Variants in Exome Sequencing Studies. PLoS 
Genetics, 10(3), e1004237. 
 
Yamaji, Y., Yoshida, S., Ishikawa, K., Sengoku, A., Sato, K., Yoshida, A., Kuwahara, R., 
Ohuchida, K., Oki, E., Enaida, H., Fujisawa, K., Kono, T. and Ishibashi, T. (2008). TEM7 (PLXDC1) 
in Neovascular Endothelial Cells of Fibrovascular Membranes from Patients with Proliferative 
Diabetic Retinopathy. Investigative Ophthalmology & Visual Science, July 2008, Vol. 49, No. 7: 
3151-3157. 
 
Yi, N. (2010). Statistical Analysis of Genetic Interactions. Genet Res (Camb).December; 92(5-
6):443-459.  
 
Zhao, L., Patel, S., Pei, J and Zhang, K. (2013). Antagonizing Wnt pathway in Diabetic 
Retinopathy. Diabetes, Vol. 62 pp. 3993-3995. 
 
  
 97 
 
 
 
APPENDiX 
 
  
 98 
 
Table I: Patient Characterization. Information for sex, actual age at the time of the study, 
approximate Diabetes Duration (years), the presence or absence of DR, the ETDR level and glycated 
haemoglobin % is represented. 
 
  
Exome ID 
Sex 
(M=1; 
F=0) 
Actual Age 
(years) 
Approximate 
Diabetes Duration                 
(years) 
Diabetic 
Retinopathy         
(1=DR; 
0=nonDR) 
ETDR 
level 
Glycated 
Hemoglobin 
(%) 
EX1 1 64 9 0 12 10,2 
EX2 1 70 23 1 43 9,3 
EX4 1 72 14 1 35 11 
EX6 0 58 13 0 14 8,5 
EX7 0 70 33 1 90 7,1 
EX9 1 48 12 1 35 9,9 
EX10 1 61 21 1 90 12,6 
EX11 1 65 12 1 35 7,8 
EX12 1 56 6 1 35 6,3 
EX13 0 50 3 0 12 17,3 
EX16 1 74 5 0 15 5,2 
EX17 1 68 17 1 43 8,6 
EX18 1 68 10 0 15 6,6 
EX19 1 70 23 0 12 10,3 
EX21 0 58 9 0 12 14,3 
EX23 0 63 16 1 90 6,5 
EX24 0 65 22 1 35 10,8 
EX26 0 53 29 1 35 8,4 
EX27 0 77 19 0 15 9,8 
EX28 0 73 4 0 12 6,9 
EX29 1 62 13 0 15 7,6 
EX30 1 66 22 1 35 11,2 
EX33 1 71 13 1 43 8,3 
EX34 0 65 24 1 43 8,9 
EX35 0 52 9 0 12 7,7 
EX36 0 65 9 0 12 9,3 
EX37 1 64 22 1 43 7,7 
EX38 0 74 5 0 12 10,5 
EX39 1 65 23 1 47 8,5 
EX40 0 54 17 1 20 11,5 
EX41 1 76 41 1 43 9,7 
EX42 0 58 17 1 25 12,3 
EX43 1 70 5 1 47 9 
EX44 0 57 33 0 12 11 
EX45 1 70 20 0 15 9,3 
EX46 0 62 13 1 35 7,7 
EX47 0 65 23 1 35 10,9 
EX48 1 55 9 1 53 10,8 
EX49 0 70 27 1 53 11,9 
EX50 0 58 15 0 12 9 
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Table II. Quality Control Results after DNA extraction. Y - Yes 
Sample 
Fluorescence 
Values (ng/uL) 
Absorvance 
values 
260/280 
Absorvance 
values 
260/230 
Purification Procedure 
(Isopropanol Precipitation) 
Ex1 25,1 1,71 1,25 Y 
Ex2 39,3 1,85 2,20   
Ex4 23,6 1,75 1,56 Y 
Ex6 30,8 1,75 1,91   
Ex7 32,3 1,81 1,71   
Ex9 36,0 1,78 1,65 Y 
Ex10 63,1 7,83 2,06   
Ex11 6,5 1,63 0,95 Y 
Ex12 22,3 1,73 1,04 Y 
Ex13 43,9 1,84 2,21   
Ex16 63,0 1,79 1,89   
Ex17 56,3 1,80 2,10   
Ex18 30,2 1,85 1,73   
Ex19 38,6 1,79 1,84   
Ex21 29,3 1,66 1,09 Y 
Ex23 63,9 1,78 1,85   
Ex24 36,1 1,85 2,09   
Ex26 65,8 1,73 1,59 Y 
Ex27 48,5 1,79 1,67 Y 
Ex28 49,8 1,79 1,57 Y 
Ex29 53,8 1,76 1,43 Y 
Ex30 61,3 1,79 1,61 Y 
Ex33 39,4 1,81 1,24 Y 
Ex34 58,8 1,77 1,51 Y 
Ex35 72,6 1,80 1,68 Y 
Ex36 42,2 1,80 1,97   
Ex37 35,6 1,78 1,60 Y 
Ex38 75,8 1,81 1,87   
Ex39 31,6 1,79 1,96   
Ex40 41,3 1,77 1,40 Y 
Ex41 48,8 1,84 2,13   
Ex42 52,7 1,78 1,92   
Ex43 67,5 1,79 2,12   
Ex44 46,7 1,79 1,97   
Ex45 56,6 1,83 1,99   
Ex46 40,9 1,75 2,10   
Ex47 75,2 1,79 2,22   
Ex48 40,2 1,80 1,79   
Ex49 54,9 1,76 1,78   
Ex50 26,3 1,77 1,39 Y 
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Table III. IonXpress barcode (MID) attribution to samples. 
Sample IonXpress Barcode 
EX1 001 
EX2 002 
EX4 004 
EX6 006 
EX7 007 
EX9 009 
EX10 010 
EX11 011 
EX12 012 
EX13 013 
EX16 016 
EX17 001 
EX18 002 
EX19 003 
EX21 005 
EX23 007 
EX24 008 
EX26 010 
EX27 011 
EX28 012 
EX29 013 
EX30 014 
EX33 001 
EX34 002 
EX35 003 
EX36 004 
EX37 005 
EX38 006 
EX39 007 
EX40 008 
EX41 009 
EX42 010 
EX43 011 
EX44 012 
EX45 013 
EX46 014 
EX47 015 
EX48 016 
EX49 001 
EX50 002 
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Figure A. Coverage Depth for all 40 exomes sequenced 
 
 
 
Figure B. On Target (%) for all 40 exomes sequenced. 
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MARKER_ID NUM_PASS_VARS NUM_SING_VARS PVALUE
17:72365698-72368711_GPR142 2 1 0,00023708
20:47864230-47887168_ZNFX1 3 3 0,00094832
6:157488325-157525120_ARID1B 2 1 0,00094832
11:64519437-64527310_PYGM 4 3 0,0010121
14:105169564-105185146_INF2 5 5 0,0025023
1:247614602-247615148_OR2B11 3 2 0,0025469
17:63149547-63189687_RGS9 3 3 0,0026079
10:74899499-74908110_ECD 2 2 0,002845
1:153587865-153587865_S100A14 1 0 0,002845
17:3101591-3101617_OR1A2 2 2 0,002845
17:39412071-39412125_KRTAP9-9 2 2 0,002845
17:39780752-39780752_KRT17 1 0 0,002845
17:60814250-60837337_MARCH10 2 2 0,002845
4:140640704-140640704_MAML3 1 0 0,002845
5:178555044-178771135_ADAMTS2 2 2 0,002845
22:26164394-26423535_MYO18B 7 6 0,0029763
6:7373434-7387238_CAGE1 3 3 0,0037933
16:2287215-2287632_DNASE1L2 3 2 0,0052564
10:73964269-73970502_ASCC1 2 2 0,0056899
1:86249980-86591175_COL24A1 2 2 0,0056899
2:130931095-130931167_SMPD4 1 0 0,0056899
2:70900443-70933491_ADD2 2 2 0,0056899
3:36756863-36780081_DCLK3 2 2 0,0056899
16:14956982-14989425_NOMO1 3 2 0,0063792
1:201169532-201185638_IGFN1 3 2 0,0065298
11:56143113-56143943_OR8U1 2 0 0,007993
15:45389453-45399036_DUOX2 4 4 0,007993
13:25254891-25284616_ATP12A 6 5 0,0081569
19:15563529-15563934_RASAL3 2 1 0,0097202
19:20228996-20229780_ZNF90 4 4 0,0097202
19:34180082-34262952_CHST8 3 3 0,0097202
7:1586617-1590576_TMEM184A 2 1 0,0097202
10:125506302-125558631_CPXM2 2 2 0,01138
1:247695273-247695756_OR2C3 3 3 0,01138
19:44681046-44681717_ZNF226 3 3 0,01138
21:44480591-44480591_CBS 1 0 0,01138
22:45128123-45255629_ARHGAP8 2 2 0,01138
22:45128123-45255629_PRR5-ARHGAP8 2 2 0,01138
2:73172214-73188370_SFXN5 3 3 0,01138
5:1254510-1254510_TERT 1 0 0,01138
9:27524515-27524731_IFNK 2 2 0,01138
9:94171786-94172507_NFIL3 2 2 0,01138
8:130761778-130774958_GSDMC 2 1 0,011678
15:63920891-64041689_HERC1 3 3 0,012565
10:116207642-116251624_ABLIM1 3 2 0,015884
11:62984850-62997031_SLC22A25 2 1 0,015884
1:47726135-47746113_STIL 3 3 0,015884
7:150164346-150174507_GIMAP8 2 1 0,015884
11:62652950-62655818_SLC3A2 2 2 0,01707
19:19308064-19310047_RFXANK 1 0 0,01707
20:43723614-43723669_KCNS1 2 2 0,01707
20:57767960-57828134_ZNF831 2 2 0,01707
21:45175604-45175847_PDXK 2 2 0,01707
22:21344733-21351614_LZTR1 2 2 0,01707
4:983556-983684_SLC26A1 2 2 0,01707
9:75355093-75355093_TMC1 1 0 0,01707
6:12122645-12164308_HIVEP1 4 4 0,019427
1:10713845-10720270_CASZ1 3 3 0,019678
4:152499205-152570675_FAM160A1 3 3 0,019678
1:215847545-216246585_USH2A 5 5 0,021222
10:55600221-55782754_PCDH15 3 2 0,022678
22:18300278-18371970_MICAL3 3 3 0,024182
12:110924375-110924375_FAM216A 1 0 0,025605
12:20522514-20769270_PDE3A 2 2 0,025605
1:222798106-222802261_MIA3 2 2 0,025605
1:23847537-23857060_E2F2 2 2 0,025605
14:69256441-69256441_ZFP36L1 1 0 0,025605
16:772780-775236_CCDC78 2 2 0,025605
16:8895679-8898702_PMM2 2 2 0,025605
17:43481395-43506940_ARHGAP27 2 2 0,025605
19:35616111-35624994_LGI4 2 2 0,025605
22:41537234-41574925_EP300 2 2 0,025605
2:33482545-33585796_LTBP1 2 2 0,025605
2:73303267-73315220_RAB11FIP5 2 2 0,025605
3:142395072-142402915_PLS1 2 2 0,025605
MARKER_ID NUM_PASS_VARS NUM_SING_VARS PVALUE
5:484771-492142_SLC9A3 2 2 0,025605
6:160461723-160482649_IGF2R 2 2 0,025605
9:107554255-107599376_ABCA1 3 3 0,025605
9:128678097-128678097_PBX3 1 0 0,025605
20:55027391-55033420_CASS4 3 2 0,026363
3:124826801-124906167_SLC12A8 4 3 0,027513
11:65144075-65147013_SLC25A45 1 0 0,029161
11:75298327-75298558_MAP6 3 3 0,029161
6:29407955-29408721_OR10C1 5 1 0,030427
10:103899871-103899970_PPRC1 2 2 0,034139
1:171173089-171178090_FMO2 3 3 0,034139
13:28794482-28844967_PAN3 2 2 0,034139
15:70957020-70970463_UACA 2 2 0,034139
17:19451355-19470502_SLC47A1 2 2 0,034139
18:34156497-34205521_FHOD3 2 2 0,034139
22:21799719-21800202_HIC2 2 2 0,034139
3:46563126-46574357_LRRC2 2 2 0,034139
4:2252847-2259728_MXD4 2 2 0,034139
5:140579961-140581006_PCDHB11 2 2 0,034139
6:36104494-36106712_MAPK13 1 0 0,034139
9:35740293-35740293_GBA2 1 0 0,034139
10:100182151-100202971_HPS1 3 3 0,034851
1:246078824-246078824_SMYD3 1 0 0,034851
1:3679886-3680362_CCDC27 2 1 0,034851
3:78676694-78763613_ROBO1 3 3 0,034851
9:73151752-73167838_TRPM3 1 0 0,034851
15:42106923-42116750_MAPKBP1 3 2 0,035006
1:94467548-94520733_ABCA4 4 4 0,035006
3:111603901-111672861_PHLDB2 4 2 0,036848
2:186653502-186678720_FSIP2 6 6 0,04101
19:20002603-20003486_ZNF253 2 1 0,041252
19:54973482-54974538_LENG9 3 3 0,041252
2:29287863-29297091_C2orf71 3 2 0,041252
7:123302011-123303052_LMOD2 3 3 0,041252
6:160958935-161020526_LPA 7 4 0,044196
10:82330044-82348429_SH2D4B 2 2 0,045519
10:89264706-89265292_MINPP1 2 2 0,045519
1:145301716-145304656_RP11-458D21.5 1 0 0,045519
11:63276396-63276432_LGALS12 2 2 0,045519
11:6976984-6977031_ZNF215 2 2 0,045519
12:110418705-110418705_TCHP 1 0 0,045519
12:111748192-111785678_CUX2 2 2 0,045519
1:223177972-223178706_DISP1 2 2 0,045519
12:57648716-57663716_R3HDM2 2 2 0,045519
16:113057-113713_RHBDF1 2 2 0,045519
16:3100094-3108573_MMP25 2 2 0,045519
16:89293934-89294865_ZNF778 2 2 0,045519
17:67081193-67111579_ABCA6 2 2 0,045519
17:77758597-77758597_CBX2 1 0 0,045519
19:2217094-2217786_DOT1L 2 2 0,045519
1:9657118-9673046_TMEM201 2 2 0,045519
20:24944523-24952091_APMAP 2 2 0,045519
20:57036604-57042655_APCDD1L 2 2 0,045519
21:40752359-40765192_WRB 2 2 0,045519
22:30188418-30221173_ASCC2 2 2 0,045519
22:31673116-31674324_LIMK2 2 1 0,045519
2:97270095-97270095_KANSL3 1 0 0,045519
3:121828181-121828181_CD86 1 0 0,045519
3:50331133-50332327_HYAL3 2 2 0,045519
6:27858249-27860534_HIST1H3J 2 2 0,045519
6:28093526-28097586_ZSCAN16 2 2 0,045519
9:99797981-99797981_CTSL2 1 0 0,045519
6:51640639-51923404_PKHD1 6 6 0,045542
1:231830492-231906713_DISC1 3 2 0,0456
19:38893807-38899459_FAM98C 3 2 0,0456
12:56075599-56077768_METTL7B 4 4 0,048364
14:24619811-24629557_RNF31 3 3 0,048364
15:72122642-72338423_MYO9A 3 3 0,048364
16:10971206-11002927_CIITA 3 3 0,048364
17:7910817-7915471_GUCY2D 3 2 0,048364
20:3652365-3655681_ADAM33 4 4 0,048364
2:163241287-163361057_KCNH7 3 3 0,048364
2:238483751-238483751_RAB17 1 0 0,048364
3:185906117-185990072_DGKG 3 3 0,048364
 
 
 
Figure C. Lists of rare variant accumulating genes from the quantitative test approach  
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Risk MARKER_ID (chrom: start-end_gene) PASS MARKERS BURDEN CNT PVALUE
20:47864230-47887168_ZNFX1 3 3 0,0013
6:7373434-7387238_CAGE1 3 3 0,0014
14:105169564-105185146_INF2 5 5 0,002
17:60814250-60837337_MARCH10 2 2 0,0026
6:157488325-157525120_ARID1B 2 3 0,0029
10:74899499-74908110_ECD 2 2 0,003
17:39412071-39412125_KRTAP9-9 2 2 0,0034
17:39780752-39780752_KRT17 1 2 0,0035
1:57207874-57257861_C1orf168 4 5 0,0039
21:44480591-44480591_CBS 1 2 0,0055
22:26164394-26423535_MYO18B 7 8 0,0062
2:70900443-70933491_ADD2 2 2 0,0062
14:69256441-69256441_ZFP36L1 1 2 0,0064
1:86249980-86591175_COL24A1 2 2 0,0065
20:3652365-3655681_ADAM33 4 3 0,0065
2:33482545-33585796_LTBP1 2 2 0,0067
7:150164346-150174507_GIMAP8 2 3 0,0068
1:222798106-222802261_MIA3 2 2 0,0069
10:73964269-73970502_ASCC1 2 2 0,0072
2:73172214-73188370_SFXN5 3 2 0,0077
6:12122645-12164308_HIVEP1 4 4 0,0079
12:110924375-110924375_FAM216A 1 2 0,0085
1:201169532-201185638_IGFN1 3 4 0,009
19:19308064-19310047_RFXANK 1 2 0,0107
11:62652950-62655818_SLC3A2 2 2 0,0114
3:41795902-41949348_ULK4 3 2 0,012
9:94171786-94172507_NFIL3 2 2 0,013
19:15563529-15563934_RASAL3 2 3 0,014
8:23160918-23225775_LOXL2 2 2 0,014
17:39871696-39872026_GAST 3 2 0,0141
14:74823701-74824956_VRTN 2 2 0,018
2:163241287-163361057_KCNH7 3 3 0,018
19:38572678-38684261_SIPA1L3 2 1 0,019
6:28093526-28097586_ZSCAN16 2 2 0,019
9:131038429-131038643_SWI5 3 1 0,019
1:215847545-216246585_USH2A 5 5 0,02
22:21344733-21351614_LZTR1 2 2 0,02
6:27858249-27860534_HIST1H3J 2 2 0,02
11:2437185-2439468_TRPM5 2 1 0,021
13:114083328-114083333_ADPRHL1 2 1 0,021
5:13830154-13894796_DNAH5 3 3 0,021
5:55250727-55264100_IL6ST 2 1 0,021
9:34485237-34514388_DNAI1 3 3 0,021
11:73717247-73718063_UCP3 2 1 0,022
2:219871207-219892344_CCDC108 3 3 0,022
2:88826005-88828867_C2orf51 2 2 0,022
15:51743890-51772229_DMXL2 4 4 0,023
2:73303267-73315220_RAB11FIP5 2 2 0,023
5:484771-492142_SLC9A3 2 2 0,023
X:153578465-153593616_FLNA 2 1 0,024
15:70957020-70970463_UACA 2 2 0,025
3:142395072-142402915_PLS1 2 2 0,026
9:135139790-135203803_SETX 3 2 0,026
20:57767960-57828134_ZNF831 2 2 0,027
3:33038788-33055721_GLB1 2 2 0,027
9:135102244-135102327_NTNG2 1 2 0,027
17:59949672-59988892_INTS2 3 3 0,028
20:24944523-24952091_APMAP 2 2 0,028
2:236708131-236877255_AGAP1 2 2 0,028
19:20002603-20003486_ZNF253 2 3 0,029
5:134910364-134910382_CXCL14 2 2 0,029
11:64604225-64607024_CDC42BPG 1 2 0,03
3:129694696-129695938_TRH 2 3 0,031
3:195481111-195518170_MUC4 15 13 0,031
14:31097427-31119819_SCFD1 2 2 0,032
8:71025871-71041146_NCOA2 4 6 0,032
10:116207642-116251624_ABLIM1 3 3 0,033
12:20522514-20769270_PDE3A 2 2 0,033
16:2287215-2287632_DNASE1L2 3 4 0,033
16:68914537-69056827_TMCO7 2 2 0,033
18:34156497-34205521_FHOD3 2 2 0,033
19:35616111-35624994_LGI4 2 2 0,033
14:94754804-94756669_SERPINA10 2 2 0,034
17:19451355-19470502_SLC47A1 2 2 0,034
2:86373287-86378518_IMMT 1 2 0,034
11:19247163-19258929_E2F8 5 4 0,035
22:26068297-26083642_ADRBK2 2 2 0,035
3:46563126-46574357_LRRC2 2 2 0,035
14:94953705-94964127_SERPINA12 1 2 0,037
17:76420087-76571085_DNAH17 12 12 0,037
2:202557702-202557756_MPP4 2 2 0,037
3:195594795-195597000_TNK2 3 3 0,037
5:176002294-176016152_CDHR2 4 4 0,037
13:28794482-28844967_PAN3 2 2 0,038
14:20711005-20711005_OR11H4 1 2 0,038
15:45389453-45399036_DUOX2 4 4 0,038
7:1586617-1590576_TMEM184A 2 3 0,038
11:56143113-56143943_OR8U1 2 4 0,039
17:39724414-39728051_KRT9 2 2 0,039
17:4535035-4542145_ALOX15 2 3 0,039
19:14029627-14031728_CC2D1A 3 3 0,039
4:2252847-2259728_MXD4 2 2 0,039
11:6976984-6977031_ZNF215 2 2 0,04
14:91927783-91975846_SMEK1 2 2 0,04
5:37020562-37049406_NIPBL 2 2 0,04
15:83680313-83680333_C15orf40 2 3 0,041
16:84189349-84203460_DNAAF1 2 2 0,041
9:117835900-117853210_TNC 3 3 0,041
1:901922-909428_PLEKHN1 2 3 0,042
1:9098071-9101726_SLC2A5 2 2 0,042
21:40752359-40765192_WRB 2 2 0,043
4:89408212-89425756_HERC5 2 2 0,043
8:130761778-130774958_GSDMC 2 4 0,043
9:135275596-135277136_TTF1 2 3 0,044
9:84606620-84609152_FAM75D1 5 5 0,044
6:160461723-160482649_IGF2R 2 2 0,045
10:120801896-120833251_EIF3A 2 4 0,046
12:25267613-25267613_CASC1 1 3 0,046
14:93398717-93399011_CHGA 2 3 0,046
16:64981952-65016003_CDH11 3 3 0,046
22:30856091-30857645_SEC14L3 2 2 0,046
19:12574827-12574979_CTD-2192J16.17 2 2 0,047
19:36213572-36224674_MLL4 2 2 0,047
19:11488877-11492737_EPOR 2 3 0,048
6:158910743-158923120_TULP4 3 3 0,048
10:88213499-88277502_WAPAL 2 2 0,05
16:8895679-8898702_PMM2 2 2 0,05
5:73048875-73197045_ARHGEF28 3 4 0,05
Risk MARKER_ID (chrom: start-end_gene) PASS MARKERS BURDEN CNT PVALUE
 
 
 
 
 
 
 
 
 
Figure D. List of rare variant accumulating genes from the binary test approach. 
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DNASE1L2
rs ID impact impact severity polyphen pred CADD scaled Transcript ID Transcript Name Transcript length Samples
ETDR 
Values
Disease 
Duration 
(years)
rs160550 splice_region MED None 0,12 ENST00000569184 DNASE1L2-005 762 Ex12, Ex46 35,35 6,13
rs200934792 non_syn_coding MED probably_damaging 15,21 ENST00000569184 DNASE1L2-005 762 23 90 16
rs200149634 non_syn_coding MED probably_damaging 14,44 ENST00000569184 DNASE1L2-005 762 48 53 9
DMXL2 =RC3
rs ID impact impact severity polyphen pred CADD scaled Transcript ID Transcript Name Transcript length Exomes
ETDR 
Values
Disease 
Duration 
(years)
None non_syn_coding MED benign 14,65 ENST00000449909 DMXL2-003 7465 42 25 17
rs114516513 non_syn_coding MED possibly_damaging 18,03 ENST00000449909 DMXL2-003 7465 49 53 27
None non_syn_coding MED possibly_damaging 17,19 ENST00000449909 DMXL2-003 7465 24 35 22
E2F8
rs ID impact impact severity polyphen pred CADD scaled Transcript ID Transcript Name Transcript length Samples
ETDR 
Values
Disease 
Duration 
(years)
None splice_acceptor HIGH None 16,62 ENST00000527884 E2F8-001 3432 Ex7 90 33
rs793274 non_syn_coding MED benign 3,98 ENST00000527884 E2F8-001 3432 Ex46 35 13
rs77599073 non_syn_coding MED benign 8,91 ENST00000527884 E2F8-001 3432 Ex49 53 27
rs141999878 non_syn_coding MED probably_damaging 13,21 ENST00000527884 E2F8-001 3432 Ex42 25 17
None non_syn_coding MED probably_damaging 35 ENST00000532666 E2F8-004 719 Ex49 53 27
CADD > 10
MAML3
rs ID impact impact_severity polyphen_pred
cadd_scale
d Transcript ID Transcript Name Transcript length Exomes ETDR Values
Duration 
(years)
rs4863506 non_syn_coding MED benign 3.52 ENST00000509479 MAML3-001 6844 23,10 90, 90 16, 21
S100A14
rs ID impact impact_severity polyphen_pred
cadd_scale
d Transcript ID Transcript Name Transcript length Exomes ETDR Values
Duration 
(years)
rs151066419 splice_region MED None 4.06 ENST00000368701 S100A14-002 1080 23,10 90, 90 16, 21
CASZ1
rs ID impact impact_severity polyphen_pred
cadd_scale
d Transcript ID Transcript Name Transcript length Exomes ETDR Values
Duration 
(years)
rs149552670 non_syn_coding MED benign 3.6 ENST00000344008 CASZ1-001 4405 7 90 33
rs61736955 non_syn_coding MED probably_damaging 25.7 ENST00000344008 CASZ1-001 4405 49 53 27
rs3748686 non_syn_coding MED probably_damaging 16.61 ENST00000344008 CASZ1-001 4405 17 43 17
EP300
rs ID impact impact_severity polyphen_pred
cadd_scale
d Transcript ID Transcript Name Transcript length Exomes ETDR Values
Duration 
(years)
rs140187237 non_syn_coding MED possibly_damaging 11.12 ENST00000263253 EP300-001 9585 48 53 9
None non_syn_coding MED unknown 7.58 ENST00000263253 EP300-001 9585 7 90 33
CADD > 10
 
Figure E. Information regarding rare variants accumulated in genes: DNASE1L2, DMXL2 and E2F8, 
considered biologically relevant to Diabetic Retinopathy. Cells highlighted in red refer to variants with a 
CADD score >10. 
 
Figure F. Information regarding rare variants accumulated in genes: MAML3, S100A14, CASZ1 and EP300, 
considered biologically relevant to Diabetic Retinopathy. Cells highlighted in red refer to variants with a 
CADD score >10. 
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APCDD1L
rs ID impact impact_severity polyphen_pred cadd_scaled Transcript ID Transcript Name Transcript length Exomes ETDR Values Duration 
None non_syn_coding MED benign 3.66 ENST00000439429 APCDD1L-201 2040 43 47 5
rs7265902 non_syn_coding MED possibly_damaging 21.2 ENST00000439429 APCDD1L-201 2040 48 53 9
GPR142
rs ID impact impact_severity polyphen_pred cadd_scaled Transcript ID Transcript Name Transcript length Exomes ETDR Values
Disease 
Duration 
(years)
rs145323799 non_syn_coding MED benign 17.45 ENST00000335666 GPR142-002 1437 10 90 21
rs140397567 non_syn_coding MED benign 8.99 ENST00000335666 GPR142-002 1437 23.7 90, 90 16, 33
ADAMTS2
rs ID impact impact_severity polyphen_pred cadd_scaled Transcript ID Transcript Name Transcript length Exomes ETDR Values
Disease 
Duration 
(years)
rs76488852 non_syn_coding MED benign 0.04 ENST00000251582 ADAMTS2-001 6754 23 ETDR = 90 16
rs146222244 non_syn_coding MED benign 10.79 ENST00000251582 ADAMTS2-001 6754 23 ETDR = 90 21
CADD > 10
Figure G. Information regarding rare variants accumulated in genes: APCDD1L, GPR142 and ADAMTS2, 
considered biologically relevant to Diabetic Retinopathy. Cells highlighted in red refer to variants with a 
CADD score >10. 
 
 
ASO-PCR Genotyping Results 
Electrophoresis gel results from the ASO-PCR genotyping validation of the 3 
variants in DMXL2 and E2F8 genes. 
The red arrows depict the genotype of the T2D individual with the rare variant and 
thus our heterozygote control. The blue arrows depict a T2D individual that did not 
have the variant and thus our wild type control. The result for all 20 control individuals 
are represented. Every two wells correspond to an individual/genotype. X means that 
the ASO-PCR genotyping of that sample was not efficient and would have to be 
repeated. A negative control for each ASO-PCR amplification was prepared. 
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E2F8_ rs141999878 C/A:  
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E2F8_ 11: 19247163 C/G 
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